EP2828248B1 - Flavone derivatives and their use - Google Patents
Flavone derivatives and their use Download PDFInfo
- Publication number
- EP2828248B1 EP2828248B1 EP13713752.7A EP13713752A EP2828248B1 EP 2828248 B1 EP2828248 B1 EP 2828248B1 EP 13713752 A EP13713752 A EP 13713752A EP 2828248 B1 EP2828248 B1 EP 2828248B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bj486k
- compound
- methoxy
- complex
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002212 flavone derivatives Chemical class 0.000 title description 76
- UUQJTIHOVGMQIH-UHFFFAOYSA-N ladanein Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(O)=C(OC)C=C2O1 UUQJTIHOVGMQIH-UHFFFAOYSA-N 0.000 claims description 457
- 150000001875 compounds Chemical class 0.000 claims description 104
- 241000700605 Viruses Species 0.000 claims description 97
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 64
- 208000015181 infectious disease Diseases 0.000 claims description 61
- 239000011777 magnesium Substances 0.000 claims description 59
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 48
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 36
- 230000009385 viral infection Effects 0.000 claims description 32
- 208000036142 Viral infection Diseases 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 25
- 108010036949 Cyclosporine Proteins 0.000 claims description 25
- 229930105110 Cyclosporin A Natural products 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
- 239000000460 chlorine Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- ICIJBYYMEBOTQP-UHFFFAOYSA-N n-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride Chemical compound Cl.C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ICIJBYYMEBOTQP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 229910006069 SO3H Inorganic materials 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 4
- 150000004696 coordination complex Chemical class 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- NWBNORAVIXIZTL-UHFFFAOYSA-N nitro thiocyanate Chemical group [O-][N+](=O)SC#N NWBNORAVIXIZTL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002935 telaprevir Drugs 0.000 claims description 4
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- 229960000517 boceprevir Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 3
- 229960000329 ribavirin Drugs 0.000 claims description 3
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims description 3
- 229950006081 taribavirin Drugs 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 108010078233 Thymalfasin Proteins 0.000 claims description 2
- MLESJYFEMSJZLZ-MAAOGQSESA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound C[C@@]1(F)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 MLESJYFEMSJZLZ-MAAOGQSESA-N 0.000 claims description 2
- XENHXZMAOSTXGD-DSMKLBDQSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2s)-2-amino-3-methylbutanoate;dihydrochloride Chemical compound Cl.Cl.C[C@@]1(O)[C@H](OC(=O)[C@@H](N)C(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 XENHXZMAOSTXGD-DSMKLBDQSA-N 0.000 claims description 2
- 108010080374 albuferon Proteins 0.000 claims description 2
- 229960002063 sofosbuvir Drugs 0.000 claims description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims description 2
- 108010017101 telaprevir Proteins 0.000 claims description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 2
- 229960004231 thymalfasin Drugs 0.000 claims description 2
- 229940086210 victrelis Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 100
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 73
- 229930003944 flavone Natural products 0.000 description 71
- 235000011949 flavones Nutrition 0.000 description 71
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 70
- 241000711549 Hepacivirus C Species 0.000 description 62
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 62
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- -1 flavonoid compounds Chemical class 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000003112 inhibitor Substances 0.000 description 38
- 229910001629 magnesium chloride Inorganic materials 0.000 description 38
- 239000000203 mixture Substances 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 28
- 230000000840 anti-viral effect Effects 0.000 description 27
- 230000009102 absorption Effects 0.000 description 26
- 238000010521 absorption reaction Methods 0.000 description 26
- 102100027221 CD81 antigen Human genes 0.000 description 24
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 239000011550 stock solution Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 241000725303 Human immunodeficiency virus Species 0.000 description 20
- 241000711975 Vesicular stomatitis virus Species 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 238000004448 titration Methods 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 238000010668 complexation reaction Methods 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 14
- 150000002213 flavones Chemical class 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 14
- 239000002184 metal Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000002243 precursor Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000003595 spectral effect Effects 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 9
- 241000710831 Flavivirus Species 0.000 description 9
- 235000021355 Stearic acid Nutrition 0.000 description 9
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 9
- 229960003677 chloroquine Drugs 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 241001529453 unidentified herpesvirus Species 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 229910001914 chlorine tetroxide Inorganic materials 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 6
- 0 Cc1c(*)c(N)c(*)c(N)c1N Chemical compound Cc1c(*)c(N)c(*)c(N)c1N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010052090 Renilla Luciferases Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 6
- 229910001623 magnesium bromide Inorganic materials 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-YYWVXINBSA-N DMF-d7 Substances [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 5
- 241000725619 Dengue virus Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000710781 Flaviviridae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 241000710886 West Nile virus Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009918 complex formation Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000012809 post-inoculation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000005723 virus inoculator Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- XYHIVQHSXGOAQP-UHFFFAOYSA-N 6-hydroxy-4',5,7-trimethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(O)=C(OC)C=C2O1 XYHIVQHSXGOAQP-UHFFFAOYSA-N 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 102000053028 CD36 Antigens Human genes 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZIIAJIWLQUVGHB-UHFFFAOYSA-N Circimaritin Natural products C=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 ZIIAJIWLQUVGHB-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- OBQMAEGCYPFNKQ-UHFFFAOYSA-N cirsimaritin Natural products COc1c(C)cc2OC(=CC(=O)c2c1O)c3ccc(O)cc3 OBQMAEGCYPFNKQ-UHFFFAOYSA-N 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- QCDYOIZVELGOLZ-UHFFFAOYSA-N salvigenin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C=C2O1 QCDYOIZVELGOLZ-UHFFFAOYSA-N 0.000 description 4
- ZZPHAQJIENBZOF-UHFFFAOYSA-N salvigenin Natural products COc1c(C)cc2OC(=CC(=O)c2c1O)c3ccc(C)cc3 ZZPHAQJIENBZOF-UHFFFAOYSA-N 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- WGHUNMFFLAMBJD-UHFFFAOYSA-M tetraethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC[N+](CC)(CC)CC WGHUNMFFLAMBJD-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- 108091005487 SCARB1 Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 150000002221 fluorine Chemical class 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- TXEOMVPWWMJOGT-UHFFFAOYSA-N (4-acetyloxy-3,5-dimethoxyphenyl) acetate Chemical compound COC1=CC(OC(C)=O)=CC(OC)=C1OC(C)=O TXEOMVPWWMJOGT-UHFFFAOYSA-N 0.000 description 2
- JQIYCACQAOMVTI-UHFFFAOYSA-N 1-(3,6-dihydroxy-2,4-dimethoxyphenyl)ethanone Chemical compound COC1=CC(O)=C(C(C)=O)C(OC)=C1O JQIYCACQAOMVTI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- OLBNOBQOQZRLMP-UHFFFAOYSA-N 2,6-dimethoxy-p-benzoquinone Chemical compound COC1=CC(=O)C=C(OC)C1=O OLBNOBQOQZRLMP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000005743 Elbs oxidation reaction Methods 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010008488 Glycylglycine Proteins 0.000 description 2
- 229940122750 HCV entry inhibitor Drugs 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- 241001500343 Influenzavirus C Species 0.000 description 2
- 241001661732 Isavirus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 241000519983 Marrubium peregrinum Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 240000001068 Thogoto virus Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- PBQMALAAFQMDSP-UHFFFAOYSA-N Zapotin Chemical compound C=1C(=O)C2=C(OC)C(OC)=CC=C2OC=1C1=C(OC)C=CC=C1OC PBQMALAAFQMDSP-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-L catecholate(2-) Chemical compound [O-]C1=CC=CC=C1[O-] YCIMNLLNPGFGHC-UHFFFAOYSA-L 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- IMEYGBIXGJLUIS-UHFFFAOYSA-N cirsiliol Chemical compound C=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C(O)=C1 IMEYGBIXGJLUIS-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002265 electronic spectrum Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940043257 glycylglycine Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- PASOFFRBGIVJET-YRKGHMEHSA-N (2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PASOFFRBGIVJET-YRKGHMEHSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- REBWSFKBXIVNRQ-UHFFFAOYSA-N 2-(furan-3-yl)furan Chemical group C1=COC(C2=COC=C2)=C1 REBWSFKBXIVNRQ-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- VIIYYMZOGKODQG-UHFFFAOYSA-N 2-nitrobenzene-1,4-diol Chemical compound OC1=CC=C(O)C([N+]([O-])=O)=C1 VIIYYMZOGKODQG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- JLFOFYBNCNKHOL-UHFFFAOYSA-N 3,5,6-Trihydroxy-7,4'-dimethoxyflavone Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(OC)C=C2O1 JLFOFYBNCNKHOL-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- IYBLVRRCNVHZQJ-UHFFFAOYSA-N 5-Hydroxyflavone Chemical compound C=1C(=O)C=2C(O)=CC=CC=2OC=1C1=CC=CC=C1 IYBLVRRCNVHZQJ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000003694 Baker-Venkataraman reaction Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- NUHCFYAOXYBXDS-UHFFFAOYSA-N COc(cc(c1c2O)OC(c3ccncc3)=CC1=O)c2O Chemical compound COc(cc(c1c2O)OC(c3ccncc3)=CC1=O)c2O NUHCFYAOXYBXDS-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 240000000712 Casimiroa edulis Species 0.000 description 1
- 235000003936 Casimiroa edulis Nutrition 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 201000005866 Exanthema Subitum Diseases 0.000 description 1
- 229910002553 FeIII Inorganic materials 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000005618 Fries rearrangement reaction Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 201000009758 Kunjin encephalitis Diseases 0.000 description 1
- 208000030510 Kunjin virus infectous disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000907337 Modoc virus Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000907507 Ntaya virus Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000710884 Powassan virus Species 0.000 description 1
- ISZWRZGKEWQACU-UHFFFAOYSA-N Primuletin Natural products OC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1 ISZWRZGKEWQACU-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037593 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta Human genes 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000907520 Rio Bravo virus Species 0.000 description 1
- 241000538730 Rocio Species 0.000 description 1
- 241000907329 Russian Spring-Summer encephalitis virus Species 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000120643 Tyuleniy virus Species 0.000 description 1
- 241000907508 Uganda S virus Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- FBUBVLUPUDBFME-UHFFFAOYSA-N Xanthoxylin Chemical compound COC1=CC(O)=C(C(C)=O)C(OC)=C1 FBUBVLUPUDBFME-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960001171 acetohydroxamic acid Drugs 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005354 acylalkyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- JROGBPMEKVAPEH-GXGBFOEMSA-N emetine dihydrochloride Chemical compound Cl.Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC JROGBPMEKVAPEH-GXGBFOEMSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- LHOWRPZTCLUDOI-UHFFFAOYSA-K iron(3+);triperchlorate Chemical compound [Fe+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O LHOWRPZTCLUDOI-UHFFFAOYSA-K 0.000 description 1
- FXDLIMJMHVKXAR-UHFFFAOYSA-K iron(III) nitrilotriacetate Chemical compound [Fe+3].[O-]C(=O)CN(CC([O-])=O)CC([O-])=O FXDLIMJMHVKXAR-UHFFFAOYSA-K 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002080 lysosomotropic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 238000005822 methylenation reaction Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000006699 reductive acetylation reaction Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/02—Magnesium compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives.
- the present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection.
- flavonoids Various flavonoids, methods to obtain them and their uses, e.g. to treat infectious conditions such as viral or parasite infections, are known in the art and have been widely reported in the literature.
- WO 01/03681 discloses the use of flavonoid compounds, such as the flavones cirsiliol and naringin, or coumarins in the treatment of viral or parasitic infections.
- Viruses are infectious agents that are found in virtually all life forms, including humans, animals, plants, fungi, and bacteria. Viruses often damage or kill the cells that they infect, causing disease in infected organisms. The difficulty in treating virus infections stems from the large number of variant viruses that can cause the same disease, as well as the inability of many drugs to disable a virus without disabling healthy cells.
- virus-cell fusion is mediated by viral fusion proteins operating through shared mechanisms among enveloped viruses and modulating membrane properties of host and viral membranes.
- the Flaviviridae (also referred to as flaviviruses) are a family of viruses that infect a wide range of vertebrates and are spread through arthropods, mainly ticks and mosquitoes, or are transmitted parenterally (through blood) as well as sexually and vertically (from mother to child).
- the family Flaviviridae comprises three genera: Genus Flavi, Genus Hepaci, and Genus Pesti.
- the genus Flavi includes the species Dengue Virus 1-4; West Nile Virus; Yellow Fever Virus; Tick-borne Encephalitis Virus; Japanese Encephalitis Virus; St. Louis Encephalitis Virus; Murray Valley Encephalitis Virus; Kunjin Encephalitis Virus; Rocio Encephalitis Virus; Russian Spring Summer Encephalitis Virus; Negeishi Virus; Kyasanur Forest Virus; Omsk Hemorrhagic Fever Virus; Powassan Virus; Louping Ill Virus; Rio Bravo Virus 1-7; Tyuleniy Virus; Ntaya Virus; Kenya S Virus/Zika Virus; and Modoc Virus.
- the genus Hepaci includes the species Hepatitis C Virus and Hepatitis G Virus.
- the genus Pesti contains viruses infecting non-human mammals, e. g. Bovine virus diarrhea 1-3.
- the Flaviviruses are small (about 40 - 60 nm in diameter), enveloped, single-stranded RNA viruses with linear non-segmented genomes.
- the Flaviviridae genome is infectious and on average about 9.6 to 12.3 kilobase in length - it encodes around 10 genes. Viruses in this family are considered positive (+) sense because proteins are made directly from the template strand of RNA which is present in the viral capsid.
- Flaviviridae family Major diseases caused by the Flaviviridae family include: Hepatitis C Virus Infection; Dengue fever; encephalitis; and hemorrhagic fever.
- flaviviruses can, for example, be found in Westaway EG, et al.,"Flaviviridae", Intervirology 1985; 24(4): 183-92 ; Chambers TJ and Rice CM, "Molecular biology of the flaviviruses", Microbiol Sci. 1987; 4(7): 219-23 ; and Knipe DM and Peter MH, eds. Fields Virology; 5th ed. Vol. 2; Philidelphia, PA: Wolters Kluwer Health, 2007; p. 1102-1291 .
- HIV Human immunodeficiency virus
- HIV is a retrovirus.
- Two types of HIV have been characterized: HIV-1 and HIV-2, which share a common structure. HIV is roughly spherical with a diameter of about 120 nm. It is composed of two copies of positive single-stranded RNA that codes for the virus's nine genes enclosed by a conical capsid composed of 2,000 copies of the viral protein p24, which is surrounded by a matrix composed of the viral protein p17 thereby ensuring the integrity of the virion particle and the viral envelope.
- the viral envelope contains a glycoprotein complex, which enables the virus to attach to and fuse with target cells to initiate the infectious cycle.
- HIV infects macrophages, CD4 + T cells, and dendritic cells of the host by the adsorption of glycoproteins on its surface to receptors on the target cell followed by fusion of the viral envelope with the cell membrane and the release of the HIV capsid into the cell.
- Herpesviridae are a large family of DNA viruses that cause diseases in animals, including humans. Herpesviridae can cause infections, such as oral and/or genital herpes, chickenpox and shingles, infectious mononucleosis, Burkitt's lymphoma, CNS lymphoma, retinitis, sixth disease etc. Herpesviruses all share a common structure.
- the virus particle is composed of relatively large double-stranded, linear DNA genomes encoding 100-200 genes encased within a protein cage (called capsid), which is itself wrapped in a protein layer containing both viral proteins and viral mRNAs and a lipid bilayer membrane called the envelope.
- herpesviruses are nuclear-replicating, i.e. the viral DNA is transcribed to RNA within the infected cell's nucleus. Infection is initiated when a viral particle contacts a cell with specific types of receptor molecules on the cell surface. Following binding of viral envelope glycoproteins to cell membrane receptors, the viral particle is internalized and dismantled, allowing viral DNA to migrate to the cell nucleus.
- VSV Vesicular Stomatitis Virus
- VSV is a member of the family Rhabdoviridae, genus Vesiculovirus. It is a small, compact virus, with only 11-12 kilobases in its genome. The virus carries as its genome a single-stranded, minus sense RNA. In order for the virus to replicate, it must use its own polymerase to create mRNAs and then translate those into proteins. Infected hosts usually show flu-like symptoms, e.g. fever.
- the Orthomyxoviridae are a family of RNA viruses that includes five genera: influenzavirus A, influenzavirus B, influenzavirus C, isavirus and thogotovirus. Influenzavirus A, influenzavirus B, influenzavirus C and thogotoviruses cause influenza in vertebrats, including humans. Isaviruses infect salmon. Viruses of this family contain 6 to 8 segments of linear negative-sense single stranded RNA. The total genome length is 12000-15000 nucleotides. The viruses of this family are very similar in structure and the envelope can occur in spherical and filamentous forms. In general, the virus's morphology is spherical with particles (virions) 50 to 120 nm in diameter, or filamentous virions 20 nm in diameter and 200 to 300 (-3000) nm long.
- an aim of the present invention to provide novel antiviral compounds that are preferably inhibitors of virus entry, preferably of enveloped viruses, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses.
- enveloped viruses such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses.
- flaviviruses e.g. hepatitis C virus (HCV), dengue virus, west nile virus
- HCV human immunodeficiency virus
- herpesviruses e.g. vesicular stomatitis virus (VSV), or influenza viruses.
- the present invention was made in view of the prior art and the needs described above, and, therefore, the object of the present invention is to provide novel alternative means for treating and/or preventing viral infections, preferably viral infections with enveloped viruses, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses.
- flaviviruses e.g. hepatitis C virus (HCV), dengue virus, west nile virus
- HCV human immunodeficiency virus
- herpesviruses vesicular stomatitis virus (VSV), or influenza viruses.
- VSV vesicular stomatitis virus
- Another objects of the present invention are to provide a pharmaceutical composition for use in the treatment and/or prevention of viral infections, preferably infections with enveloped viruses, to provide a combinatorial composition, comprising compounds for treating such viral infections.
- the inventors established that certain compounds prevent virus life cycle steps, e.g. HCV, VSV and HIV-1 life cycle steps, subsequent to virus binding and prior to viral RNA translation and RNA replication.
- virus life cycle steps e.g. HCV, VSV and HIV-1 life cycle steps
- the inventors showed that combined administration of certain compounds and cyclosporine A had a synergistic effect in inhibition of HCV infection.
- R 1 and R 2 are transient masked hydroxyl groups, cleavable under physiological conditions, taken together to form one of the following groups, like methylenedioxy, ethylenedioxy, diisopropylsilyl, diterbutylsilyl, acetonide, phenyl ketal, carbonate, sulfite, sulfate, phenyl O,O,O-orthoester, methyl O,O,O-orthoester, phenyl O,O,N-orthoester, methyl O,O,N-orthoester groups, as illustrated below: wherein
- the present invention is directed to a compound of the general formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is: R 1 is a group OR 5 and R 2 is an oxygen atom that is taken together with the ⁇ -carbonyl unit to form a metal complex of the general formula (II): wherein
- a "pharmaceutically acceptable salt” of a compound disclosed herein preferably is an acid or base salt that is generally considered in the art to be suitable for use in contact with the tissues of human beings or animals without excessive toxicity or carcinogenicity, and preferably without irritation, allergic response, or other problem or complication.
- Such salts include inorganic and organic acid salts of basic residues such as amines or pyridines, as well as alkali or organic salts of acidic residues such as carboxylic acids or basic residues such as phenols or catechols, thiophenols.
- Suitable pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzene sulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenylacetic, alkanoic such as acetic, HOOC-(CH 2 ) n -COOH where n is any integer from 0 to 4, i.e., 0, 1, 2, 3, or 4, and the like.
- acids such as hydrochloric, phosphoric
- pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, zinc, magnesium, lithium and ammonium.
- a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile, is preferred.
- each compound of formula (I) may, but need not, be present as a hydrate, solvate or non-covalent complex.
- the various crystal forms and polymorphs are within the scope of the present invention.
- a “substituent,” as used herein, refers to a molecular moiety that is covalently bonded to an atom within a molecule of interest, e.g. to a compound of formula (I) or a prodrug thereof.
- a "ring substituent” may be a moiety such as a halogen atom, alkyl group, haloalkyl group or other substituent described herein that is covalently bonded to an atom, preferably a carbon or nitrogen atom, that is a ring member.
- substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound, i.e., a compound that can be isolated, characterized and tested for biological activity.
- a pyridyl group substituted by oxo is a pyridone.
- alkyl preferably refers to a saturated, straight-chain or branched hydrocarbon group that contains from 1 to 20 carbon atoms, preferably from 1 to 12 carbon atoms, more preferably from 1 to 6 carbon atoms, for example a methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, 2,2-dimethylbutyl, n-octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, or dodecyl group.
- alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 20 carbon atoms, preferably from 2 to 12 carbon atoms, more preferably from 2 to 6 carbon atoms, for example an ethenyl, allyl, acetylenyl, propargyl, isoprenyl or hex-2-enyl group.
- alkenyl groups have one or two, more preferably one, double bond(s) and alkynyl groups have one or two, more preferably one, triple bond(s).
- heteroalkyl preferably refers to an alkyl, alkenyl or alkynyl group, for example heteroalkenyl, heteroalkynyl, in which one or more, preferably 1, 2 or 3 carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulphur atom, preferably oxygen, sulphur or nitrogen.
- heteroalkyl for example, encompasses an alkoxy group.
- An alkoxy group denotes an alkyl group linked to oxygen thus: -O-alkyl.
- heteroalkyl preferably refers to a carboxylic acid or to a group derived from a carboxylic acid such as, for example, acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide, alkylcarbamoylalkyl, alkylcarbamoyloxyalkyl, alkylureidoalkyl, or alkoxycarbonyloxy.
- heteroalkyl groups are groups of formulas -S-Y a' -L, -S-Y a' -CO-NR a' R b' , -Y a' -NR c' -CO-NR a' R b' , -Y a' -NR c' -CO-O-R d' , -Y a' -NR c' -CO-R d' , -Y a' -NR c' -CO-NR d' -L, -Y a' -NR c' -CS-NR d' -L, -Y a' -O-CO-NR a' R b' , -Y a' -CO-NR a' R b' , -O-Y a' -CO-NR a' R b' , -O-Y a' -CO-NR a' R b' , -O-
- heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, tert -butyloxy, methoxymethyl, ethoxymethyl, methoxyethyl, methyl amino, ethylamino, dimethylamino, diethylamino, isopropylethylamino, methylaminomethyl, ethylaminomethyl, diisopropylaminoethyl, enol ether, dimethylaminomethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxycarbonyl, isobutyrylamino-methyl, N-ethyl-N-methylcarbamoyl and N-methylcarbamoyl.
- heteroalkyl groups are nitrile, isonitrile, cyanate, thiocyanate, isocyanate, isothiocyanate and alkylnitrile groups.
- An example of a heteroalkylene group is a group of formulas -CH 2 CH(OH)- or -CONH-.
- cycloalkyl preferably refers to a saturated or partially unsaturated cyclic group that contains one or more rings, preferably 1 or 2, containing from 3 to 14 ring carbon atoms, preferably from 3 to 10, more preferably 3, 4, 5, 6 or 7, ring carbon atoms.
- a partially unsaturated cyclic group has one, two or more double bonds, such as a cycloalkenyl group.
- Examples of a cycloalkyl group are a cyclopropyl, cyclobutyl, cyclopentyl, spiro[4,5]decanyl, norbornyl, cyclohexyl, cyclopentenyl, cyclohexadienyl, decalinyl, bicyclo[4.3.0]nonyl, tetralin, cyclopentylcyclohexyl, fluorocyclohexyl or cyclohex-2-enyl group.
- heterocycloalkyl preferably refers to a cycloalkyl group as defined above in which one or more, preferably 1, 2 or 3, ring carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom, preferably oxygen, sulphur or nitrogen.
- a heterocycloalkyl group has preferably 1 or 2 ring(s) containing from 3 to 10, more preferably 3, 4, 5, 6 or 7, ring atoms.
- Examples are a piperidyl, piperazinyl, morpholinyl, urotropinyl, pyrrolidinyl, tetrahydro-thiophenyl, tetrahydropyranyl, tetrahydrofuryl or 2-pyrazolinyl group and also a lactam, a lactone, a cyclic imide and a cyclic anhydride.
- alkylcycloalkyl preferably refers to a group containing both cycloalkyl and also an alkyl, alkenyl or alkynyl group in accordance with the above definitions, for example alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkynylcycloalkyl groups.
- An alkylcycloalkyl group preferably contains a cycloalkyl group that contains one or two ring systems having from 3 to 10, preferably 3, 4, 5, 6 or 7, carbon atoms, and one or two alkyl, alkenyl or alkynyl groups having 1 or 2 to 6 carbon atoms, the cyclic groups being optionally substituted.
- heteroalkylcycloalkyl preferably refers to alkylcycloalkyl groups as defined above in which one or more, preferably 1, 2 or 3, carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom, preferably oxygen, sulphur or nitrogen.
- a heteroalkylcycloalkyl group preferably contains 1 or 2 ring systems having from 3 to 10, preferably 3, 4, 5, 6 or 7, ring atoms, and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups having from 1 or 2 to 6 carbon atoms.
- Examples of such groups are alkylheterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkenyl, alkenylheterocycloalkyl, alkynylheterocycloalkyl, heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and heteroalkylheterocycloalkenyl, the cyclic groups being optionally substituted and saturated or mono-, di- or tri-unsaturated.
- aryl or Ar preferably refers to an aromatic group that contains one or more rings containing from 6 to 14 ring carbon atoms, preferably from 6 to 10, more preferably 6, ring carbon atoms. Examples are a phenyl, naphthyl, biphenyl, or anilinyl group.
- heteroaryl preferably refers to an aromatic group that contains one or more rings containing from 5 to 14 ring atoms, preferably from 5 to 10, more preferably 5 or 6, ring atoms, and contains one or more, preferably 1, 2, 3 or 4, oxygen, nitrogen, phosphorus or sulphur ring atoms, preferably O, S or N.
- Examples are 4-pyridyl, 2-imidazolyl, 3-phenylpyrrolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl, pyridazinyl, quinolinyl, purinyl, carbazolyl, acridinyl, pyrimidyl, 2,3'-bifuryl, 3-pyrazolyl and isoquinolinyl.
- aralkyl preferably refers to a group containing both aryl and also alkyl, alkenyl, alkynyl and/or cycloalkyl groups in accordance with the above definitions, such as, for example, arylalkyl, arylalkenyl, arylalkynyl, arylcycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups.
- aralkyls are toluene, xylene, mesitylene, styrene, benzyl, 1H-indene, tetralin, dihydronaphthalene, phenylcyclopentyl, cumene, cyclohexylphenyl, fluorene and indan.
- An aralkyl group preferably contains one or two aromatic ring systems, 1 or 2 rings, containing from 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms.
- heteroaralkyl preferably refers to an aralkyl group as defined above in which one or more, preferably 1, 2, 3 or 4, carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulphur atom, preferably oxygen, sulphur or nitrogen, that is to say to groups containing both aryl or heteroaryl and also alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups in accordance with the above definitions.
- a heteroaralkyl group preferably contains one or two aromatic ring systems, 1 or 2 rings, containing from 5 or 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms, 1, 2, 3 or 4 of those carbon atoms having been replaced each independently of the others by oxygen, sulphur or nitrogen atoms.
- heteroaralkyl groups are aryloxy, arylheteroalkyl, arylheterocycloalkyl, arylheterocyclo-alkenyl, arylalkylheterocycloalkyl, arylalkenylheterocycloalkyl, arylalkynylheterocycloalkyl, arylalkyl-heterocycloalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroarylheteroalkyl, hetero-arylcycloalkyl, heteroarylcycloalkenyl, heteroarylheterocycloalkyl, heteroarylheterocycloalkenyl, hetero-arylalkylcycloalkyl, heteroarylheterocycloalkenyl, hetero-arylalkylcycloalkyl, heteroarylalkylheterocycloalkenyl, hetero-arylalkyl
- substituted alkyl 2,2,2-trichloroethyl or trifluoromethyl
- substituted aryl (or substituted Ar) are 2-fluorophenyl, 3-nitrophenyl or 4-hydroxyphenyl.
- halogen or "halogen atom” as preferably used herein means fluorine, chlorine, bromine, iodine.
- a wording defining the limits of a range of length such as, e. g., "from 1 to 5" means any integer from 1 to 5, i. e. 1, 2, 3, 4 and 5.
- any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.
- the present description preferably discloses a compound of the general formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is: R 1 and R 2 are taken together to form a group: wherein
- Also preferred in the present invention is a compound of the general formula (II): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein M b represents Ca 2+ , Zn 2+ , Mg 2+ , or Fe 3+ ; R 5 is a hydrogen atom or an acetyl group; and R 3 and A are defined as in the general formula (I).
- R 4 is OMe, CF 3 , OCF 3 , fluorine, chlorine, bromine, or -SO 3 H. Further preferred, R 4 is OMe, CF 3 , or OCF 3 .
- R 3 is methyl or OMe, more preferably OMe.
- Z 1 to Z 4 are each and independently selected from hydrogen atom, fluorine, chlorine, bromine, and C 3 -C 6 alkyl. Preferably, all of Z 1 to Z 4 represent hydrogen atoms.
- R a , R b , R c , R d , and R e each and independently of each other represent a hydrogen atom, an aryl or a C 1 -C 6 alkyl group. Further preferred, R a , R b , R c , R d , and R e are each and independently of each other hydrogen atom or a C 1 -C 6 alkyl group.
- compositions of general formula (I) or (II), their pharmacologically acceptable salts or solvates and hydrates also lie within the scope of the present invention, especially, their use as antiviral agents, especially for the treatment and/or prevention of an infection by an enveloped virus, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses, particularly the treatment of hepatitis C.
- flaviviruses e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses, particularly the treatment of hepatitis C.
- the present invention also relates to a compound selected from: or a compound of formula: wherein R is stearate or Cl, the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one (BJ486K):Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one above-mentioned compound, and, optionally, at least one pharmaceutically acceptable carrier(s) and/or at least one customary excipient.
- the pharmaceutical composition of the invention comprises at least one compound selected from: or one compound of formula: wherein R is stearate or Cl, or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex.
- the compound used for the prevention and/or treatment of a viral infection is a compound according to general formula (I), (II), or a compound selected from: or a compound of formula: wherein R is stearate or Cl, or is selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex.
- the invention is also directed to the use of a compound according to general formula (I) or (II) for the preparation of a medicament intended for the prevention and/or treatment of a viral infection, preferably a viral infection by enveloped virus particles.
- the invention also relates to an above-mentioned compound for use in the prevention and/or treatment of a viral infection, wherein the infection is an infection by an enveloped virus.
- compositions for use in the treatment and/or prevention of a viral infection preferably a viral infection by enveloped virus particles
- pharmaceutical composition comprises at least one compounds according to general formula (I), (II), or a compound selected from: and, optionally, at least one pharmaceutically acceptable carrier(s) and/or at least one customary excipient.
- treatment and/or prevention is preferably meant a reduction or complete inhibiton of viral replication and/or infectivity in a subject to thereby cure or prevent the symptoms associated with the viral infection.
- inhibitor any chemical or biological, natural or synthetic molecule, any composition which, whatever the mechanism, causes after administration a reduction, or even a complete inhibition, of the activity of the respective protein or member of the protein family or the expression of the corresponding gene(s) thereof.
- An inhibitor may either bind reversible or irreversible to its substrate.
- Reversible inhibitors comprise competitive inhibitors, non-competitive inhibitors, mixed-type inhibitors, uncompetitive inhibitors, slow-binding or tight-binding inhibitors, transition state analogs and multi-substrate analogs.
- a compound of the present invention may also be referred to as virus life cycle inhibitor, i.e. a compound that hampers or suppresses the initial interactions between a virus and the host cell that are essential for any virus infection.
- Carrier substances are, for example, cyclodextrins such as hydroxypropyl ⁇ -cyclodextrin, micelles or liposomes, excipients and/or adjuvants.
- Pharmaceutical compositions may additionally comprise, for example, one or more of water, buffers such as, e.g., neutral buffered saline or phosphate buffered saline, ethanol, propylene glycol, mineral oil, vegetable oil, dimethylsulfoxide, lipids, emulsifiers, carbohydrates such as e.g., glucose, mannose, sucrose or dextrans, mannitol, proteins, adjuvants, polypeptides or amino acids such as glycine, antioxidants, metal ions such as zinc(II), calcium(II) or magnesium(II) and/or preservatives.
- buffers such as, e.g., neutral buffered saline or phosphate buffered saline
- ethanol propylene
- one or more other active ingredients may, but need not, be included in the pharmaceutical compositions provided herein.
- the compounds of the invention may advantageously be employed in combination with an antibiotic, anti-fungal, or anti-viral agent, an antihistamine, a non-steroidal anti-inflammatory drug, a disease modifying anti-rheumatic drug, a cytostatic drug, a drug with smooth muscle activity modulatory activity or mixtures of the aforementioned.
- compositions may be formulated for any appropriate route of administration, including, for example, topical such as, e.g., transdermal or ocular, oral, buccal, nasal, vaginal, rectal or parenteral administration.
- parenteral as used herein includes subcutaneous, intradermal, intravascular such as, e.g., intravenous, intramuscular, spinal, intracranial, intrathecal, intraocular, periocular, intraorbital, intrasynovial and intraperitoneal injection, as well as any similar injection or infusion technique.
- compositions in a form suitable for oral use are preferred.
- compositions provided herein may be formulated as a lyophilizate.
- compositions intended for oral use may further comprise one or more components such as sweetening agents, flavoring agents, coloring agents and/or preserving agents in order to provide appealing and palatable preparations.
- Tablets contain the active ingredient in admixture with customary (physiologically acceptable) excipients that are suitable for the manufacture of tablets.
- Customary excipients include, for example, inert diluents such as, e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents such as, e.g., corn starch or alginic acid, binding agents such as, e.g., starch, gelatin or acacia, and lubricating agents such as, e.g., magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- the pharmaceutical composition of the invention may comprise at least one of the above virus life cycle inhibitors.
- the pharmaceutical composition may also comprise 2 or more of the above virus life cycle inhibitors.
- the dose of the biologically active compound according to the invention may vary within wide limits and may be adjusted to individual requirements.
- Active compounds according to the present invention are generally administered in a therapeutically effective amount. Preferred doses range from about 0.1 mg to about 140 mg per kilogram of body weight per day, and/or about 5 mg to about 7 g per patient per day.
- the daily dose may be administered as a single dose or in a plurality of doses.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- the above virus life cycle inhibitor(s) can be used in the pharmaceutical preparation in a quantity comprised between 0.01 mg and 2 g, preferably from 1 mg to 1 g, very preferably from 10 mg to 500 mg.
- the above virus life cycle inhibitor(s) can in particular be administered in doses comprised between 0.1 mg/kg and 500 mg/kg, preferably 1 mg/kg and 100 mg/kg, very preferably 10 mg/kg and 50 mg/kg.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, i.e. other drugs being used to treat the patient, and the severity of the particular disease undergoing therapy.
- the invention is also related to a combination preparation containing at least one of the above virus life cycle inhibitors and at least one further active pharmaceutical ingredient for the treatment or prophylaxis of viral infections, such as an HCV, HIV, VSV, herpes or influenza infection.
- viral infections such as an HCV, HIV, VSV, herpes or influenza infection.
- the present invention also relates to a combination preparation for use in the treatment or prophylaxis of a viral infection containing at least one above-mentioned compound, or the compound: or a pharmacologically acceptable salt, solvate, or hydrate thereof, and at least one further active pharmaceutical ingredient.
- the present invention also relates to a combination preparation for use in the treatment or prophylaxis of a viral infection containing at least one compound selected from: or one compound of formula: wherein R is stearate or Cl, or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex.
- the further active pharmaceutical ingredient is selected from cyclosporine A, pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, ribavirin, viramidine, boceprevir (Victrelis), telaprevir (Incivo), SP 30, ITX 5061, RG7128, PSI-7977, NM 283, Albuferon and/or Zadaxin, most preferably cyclosporine A.
- the combination preparation of the invention contains at least one inhibitor of cPLA2.
- cPLA2 inhibitor is a combination of at least one cPLA2 inhibitor and at least one of pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, ribavirin and viramidine.
- the above virus life cycle inhibitors used for the treatment of viral infections will have certain pharmacological properties.
- Such properties include, but are not limited to oral bioavailability, such that the preferred oral dosage forms discussed above can provide therapeutically effective levels of the compound in vivo.
- the above virus life cycle inhibitors are preferably administered to a patient orally or parenterally, and are present within at least one body fluid or tissue of the patient.
- the present disclosure further provides methods for preventing or treating patients suffering from a viral infection, especially an infection by an enveloped virus particle.
- treatment encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic, i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms, or therapeutic, i.e., after the onset of symptoms, in order to reduce the severity and/or duration of symptoms.
- the method of preventing or treating a viral infection according to the present disclosure comprises administering to a subject in need thereof an effective amount of at least one of the above virus life cycle inhibitors.
- the method comprises administration of at least one of the virus life cycle inhibitors detailed above for use in the prevention and/or treatment of HCV infection. More particularly, the method preferably comprises administration of at least one of the virus life cycle inhibitors:
- the method of preventing or treating a viral infection, e.g. HCV infection, according to the present disclosure may, moreover, be characterized in that the virus life cycle inhibitor is intended to be administered by oral route, by aerosol route or by injection.
- the generation of the trilithium trianion 2 of the acetophenone 1 was produced by treatment with LiHMDS (Lithium hexamethyldisilylazide).
- LiHMDS Lithium hexamethyldisilylazide
- the crude intermediates 6, 7, 8 were heated at 95 - 100 °C in the presence of glacial acetic acid containing 0.5% sulfuric acid for 3.5 h to provide the flavone 9 (in the case of 6 ) and 6h to provide flavones 11, 12 (in the case of 7, 8, respectively).
- flavone 13 compound 13 or BJ486K
- BJ486K is the synthetic counterpart of the structurally identical flavonoid MP03 (also known as ladanein) isolated from plant extracts of Marrubium peregrinum Lamiaceae ) after hydrolysis by methanol in high 82% yield as well as the demethylation step of flavones 11, 12 to afford 14 and 15 in 93% yield and 27% yield, respectively.
- Purification of final very pure flavones was performed by low pressure column chromatographic techniques (Sephadex LH20 and CH 2 Cl 2 /CH 3 OH gradients) under nitrogen, and the structures elucidated by NMR and ESI-MS.
- Reagents and conditions a ) Zinc, Ac 2 O, HCl, 5 min (Yield : 91%); b ) BF 3 -Et 2 O, 120°C, 3h (Yield : 53%); i ) (1) NaOH, K 2 S 2 O 8 , 20 °C, 7 days, (2) Na 2 SO 3 (3) HCl; ii ) LiHMDS, THF, - 78°C, 1 h, - 10 °C, 2h; iii ) (1) 3a or 3b or 3c, THF, -78 °C (1 h) to 20 °C (overnight), (2) HCl; iv ) AcOH, H 2 SO 4 , 95 °C- 100 °C, 3.5 h (for 9 ) or 6h (for 11,12 ); v ) THF, LiOH, 20 °C, 2 h; vi ) (1) BBr 3 , CH 2 Cl 2 , 0 °C,
- the synthesis starts with a reductive acetylation of the 2,6-dimethoxy-1,4-benzoquinone ( 1 ) in the presence of Zn to yield the diacetate 2 with a quantitative yield.
- Product 2 undergoes a Fries rearrangement with boron trifluoride etherate in toluene to form the initial precursor of the flavone 3 with 70 % yield after a recrystallization. Both these reactions have been performed with more than 10 g of starting material.
- the initial precursor is deprotonated in the presence of LiHMDS and undergoes a Baker-Venkataraman reaction in the presence of benzoyl chloride. Without further purification, the heterocycle is formed by heating in acetic acid and sulfuric acid.
- the final precursor is formed by cleaving the ester bond using LiOH, yielding the flavone 6 with 61 % yield from the initial precursor 3.
- No silica gel column chromatography is needed thanks to an acid-base work-up which simplifies the purification. Therefore, the desired product is obtained by a simple recrystallization.
- the target molecule BJ486K is synthesized with 80 % yield by means of a selective demethylation using magnesium bromide in acetonitrile. To protect the flavone from oxidation, a magnesium complex was designed and prepared in the final step g).
- the solution was poured into a mixture of crushed ice and concentrated HCl, extracted three times with CH 2 Cl 2 , dried over magnesium sulfate and concentrated under reduced pressure to yield a brown solid.
- the solid was then dissolved in acetic acid (40 mL), H 2 SO 4 (0.5 mL) was added and the reaction was heated at 95 °C for 3.5 h. Then, the solvent was evaporated under reduced pressure, water was added and the aqueous phase was extracted three times with CH 2 Cl 2 . The organic phase was dried over magnesium sulfate and the solvent was evaporated under reduced pressure to yield a dark brown solid.
- the solid was then dissolved in THF (50 mL), and a solution of LiOH (700 mg, 29.23 mmol, excess) in MeOH (15 mL) was added. The reaction was stirred at room temperature for 2 h. The solution was poured into water and acetic acid was added until pH 5. The aqueous phase was extracted three times with CH 2 Cl 2 , then the organic phase was thoroughly washed with a 0.5 M solution of NaOH. The aqueous phase was then acidified to neutral pH with a 1 M solution of HCl and the aqueous phase was extracted three times with CH 2 Cl 2 .
- Magnesium stearate complex of XM148 (XM150). Magnesium stearate (54.8 mg, 0.093 mmol, 0.94 equiv.) was added to a solution of 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one (30.9 mg, 0.10 mmol, 1 equiv.) in dioxane (8 mL) at 100 °C. The mixture was heated for one hour and the colour changed from yellow to orange. The solvent was evaporated under reduced pressure and the solid recrystallized in acetonitrile to yield an orange solid.
- Magnesium chloride complex of XM148 (XM156).
- MgCl 2 (163.3 mg, 0.8 mmol, 5 equiv.) was added to a solution of 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one (50.5 mg, 0.16 mmol, 1 equiv.) in acetonitrile.
- the mixture was stirred at 80 °C during an hour. The colour of the mixture changed from yellow to orange.
- the solvent was evaporated under reduced pressure to yield an orange solid.
- Huh7-Lunet/CD81 cells a derivative of Huh-7 cells highly permissive for HCV RNA replication and infection ( Koutsoudakis et al., J.Virol. 2007;81:588-598 ), were cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) with 10% fetal bovine serum (FCS Gold, PAA, Coelbe, Germany), 1x non-essential amino acids (Invitrogen), 100 ⁇ g/ml streptomycin (Invitrogen) and 100 IU/ml penicillin (Invitrogen), 2 mM L-glutamine (Invitrogen) and 750 ⁇ g/ml geneticin (Carl Roth, Germany).
- DMEM Dulbecco's modified Eagle medium
- FCS Gold 10% fetal bovine serum
- FCS Gold fetal bovine serum
- 1x non-essential amino acids Invitrogen
- 100 ⁇ g/ml streptomycin Invitrog
- Huh7-Lunet/CD81 cells were infected with reporter virus particles essentially as described recently ( Koutsoudakis et al., J.Virol. 2006; 80: 5308-5320 ). Briefly, for inoculation with firefly luciferase reporter virus particles (Luc-Jc1) and Renilla reporter viruses (JcR-2a ( Reiss et al., Cell host & microbe 2011; 9: 32-45 ) and GT1-6, see plasmids below), Huh7-Lunet/CD81 cells were seeded at a density of 6 ⁇ 10e4 cells per well of a 12-well plate or 6.6 ⁇ 10e3 cells per well of a 96-well plate 24h prior to inoculation.
- Huh7-Lunet/CD81 cells were seeded at a density of 6 ⁇ 10e4 cells per well of a 12-well plate or 6.6 ⁇ 10e3 cells per well of a 96-well plate 24h prior to inoculation.
- virus particles were pretreated with the inhibitors for 1h at 37°C.
- Cells were inoculated for 4h at 37°C, viral inoculum was replaced by fresh culture fluid and infection was quantified 48h or 72h after virus inoculation using luciferase assays.
- JcR-2a is a monocistronic reporter virus derived from the Jc1 chimera that expresses a Renilla luciferase (RLuc) that is fused N-terminally with the 16 N-terminal residues of the core protein.
- RLuc is connected to the Jc1 open reading frame through the foot-and-mouth disease virus (FMDV) 2A peptide coding region which liberates the reporter from the downstream HCV proteins.
- FMDV foot-and-mouth disease virus
- chimeric HCV open reading frames encoding core, E1, E2, p7 and NS2 of the GT1a isolate H77C, the GT1b isolate J4, the GT2b isolate J8, the GT3a isolate S52, the GT4a isolate ED43, the GT5a isolate SA13, or the GT6a isolate HK6a, respectively, followed by JFH1-derived NS3 to NS5B genes were cloned downstream of the R2a-reportergene cassette.
- the resulting novel monocistronic Renilla luciferase reportervirus genomes were designated H77c/1a/R2a, J4/1b/R2a, J8/2b/R2a, S52/3a/R2a, ED43/4a/R2a, SA13/5a/R2a, HK6a/6a/R2a.
- VSV-GFP Replication competent GFP-tagged vesicular stomatitis virus
- VSV infection a recombinant vesicular stomatitis virus expressing enhanced green fluorescent protein designated VSV*M Q .
- This virus carries four attenuating mutations in the M protein, and expresses GFP from an additional transcriptional unit located between G and L.
- VSV*M Q infected cells were identified by detection of GFP-autofluorescence using a Olympus IX-81 microscope.
- Virus titers (50% tissue culture infective dose [TCID 50 /ml]) were calculated based on the method of Spearman and Kärber.
- Huh7-Lunet/CD81 cells were transfected with Jc1 RNA and seeded on a 6-well plate. Compounds were added 4h later. At 48h after transfection, cell culture supernatant was harvested and used for measuring the extracellular core amount. Cells were washed once with PBS, scraped and centrifuged for 5 min at 1000 ⁇ g. Cell pellets were resuspended in 500 ⁇ l fresh culture fluid and subjected to three cycles of freeze and thaw using liquid nitrogen and a 37°C thermo block. Samples were than centrifuged at 10,000xg for 10 min to remove cell debris and the core amount was measured (intracellular core protein) using the ARCHITECT HCV Core AG test (Abbott, Wiesbaden, Germany) according to the instructions of the manufacturer.
- Cytotoxicity was measured using the CytoTox-Glo cytotoxicity assay (Promega, Mannheim, Germany) as described by the manufacturer employing a plate luminometer Centro XS LB960 (Berthold, Freiburg, Germany) according to the manufacturer's instructions.
- JcR-2a virus particles were incubated with Huh7-Lunet/CD81 cells seeded as described above for 1h at 4°C to synchronize cell entry.
- Various inhibitors including 50 ⁇ g/ml heparin (Sigma-Aldrich), CD81-specific antibody JS-81 (2 ⁇ g/ml; Becton Dickinson), ITX 5061 (10 ⁇ M) or BJ486K (20 ⁇ M), were added during virus inoculation (protocol 1) or at indicated time points after virus inoculation (protocol 2-8). After 4h inhibitor treatment, medium was changed to fresh culture fluid without inhibitors and the cells were lysed 48h after inoculation as described above. Efficiency of infection was determined by luciferase assay using a tube luminometer (Lumat LB9507, Berthold, Freiburg, Germany).
- Virus titers were measured using the limiting dilution assay as described recently ( Steinmann et al., J.Virol. 2008; 82: 7034-7046 ). Virus titers (50% tissue culture infective dose [TCID 50 /ml]) were calculated based on the method of Spearman and Kärber ( Spearman C., British Journal of Psychology 1908; 2: 227-242 ; Kärber G., Archiv für experimentelle Pathologie und Pharmakologie 1931; 162: 480-487 ).
- liver tissue from patients seronegative for HCV, hepatitis B virus, and human immunodeficiency virus (HIV) was obtained from adult patients undergoing partial hepatectomy for the therapy of metastases.
- HCV human immunodeficiency virus
- Experimental procedures were carried out in accordance with French Laws and Regulations.
- Hepatocytes were isolated by a two-step perfusion technique and maintained in primary culture as described previously ( Podevin et al., Gastroenterology 2010; 139: 1355-64 ). Cells were inoculated with Con1/C3-HCV ( Pietschmann et al., Proc. Natl. Acad. Sci.
- BJ486K inhibits HCV cell entry but not RNA replication or virus production
- BJ486K affects virus assembly or release we transfected Huh7-Lunet/CD81 cells with Jc1 RNA and quantified intra- and extracellular levels of core protein 48h after transfection ( Figure 2B ).
- both quinidine and the grapefruit flavonoid naringenin two assembly inhibitors recently identified using the JFH1-based infection system, selectively reduced extracellular levels of core protein by more than 100- or ca. 5-fold, respectively, thus confirming their interference with HCV virus production.
- BJ486K reduced neither intracellular nor extracellular core protein levels up to a dose of 20 ⁇ M, which is 10-fold higher than the determined IC50 value ( Figure 1 ).
- BJ486K is not affected by viral resistance against a SR-BI-targeting entry inhibitor, inhibits HCV of all major genotypes and impedes infection of primary human hepatocytes.
- Syder et al. recently reported that a specific mutation within the HCV envelope protein E2 (G451R) that is known to reduce viral dependency on SR-BI for cell entry (J.Hepatol. 2011; 54: 48-55 ) at the same time reduces the susceptibility of HCV towards inhibition by ITX5061 28 .
- Efficacy of current HCV treatment is substantially influenced by viral genotype. More specifically, IFN-based therapy regimens attain sustained viral response rates of ca. 80% in patients infected with genotype 2 and 3 viruses whereas response rates among patients chronically infected with genotype 1 reach only about 50% 30 . Moreover, directly targeted antivirals in late stage clinical development vary in efficacy depending on the viral genotype. Therefore, we determined the antiviral activity of BJ486K towards HCV particles from different genotypes. To be able to resolve different response rates among these viruses with highest resolution, we created a set of novel reporter virus constructs based on the JcR-2a backbone ( Figure 3 ).
- BJ486K exerts synergistic antiviral activity with Cyclosporine A (CsA) and prevents productive infection of differentiated human hepatoma cells.
- CsA Cyclosporine A
- BJ486K would increase antiviral potency.
- BJ486K and CsA inhibitors IC 90 CI BJ486K 4,37 ⁇ M CsA >1000 ng/ml BJ486K + 100 ng/ml CsA 3,03 ⁇ M 0,793 BJ486K + 200 ng/ml CsA 2,8 ⁇ M 0,840 BJ486K + 300 ng/ml CsA 2,5 ⁇ M 0,872
- the combined glass electrode was calibrated as a hydrogen ion concentration probe by titrating known amounts of perchloric acid ( ⁇ 10 -1 M from HClO 4 , Fluka, ⁇ 70% in water) with CO 2 -free tetraethylammonium hydroxide solution ( ⁇ 10 -1 M from Et 4 NOH, Merck, ⁇ 40% in water) in MeOH/H 2 O solvent (80/20 by weight).
- the HClO 4 and NEt 4 OH solutions were freshly prepared just before use and titrated with sodium tetraborate decahydrate (B 4 Na 2 O 7 .10H 2 O, Fluka, puriss, p.a.) and potassium hydrogen phthalate (C 8 H 5 KO 3 , Fluka, puriss, p.a.), respectively, using methyl orange and with phenolphthalein (Prolabo, purum) as the indicators.
- the titration cell was thermostated at 25.0(2) °C by the flow of a Lauda E200 thermostat. A stream of argon, pre-saturated with water vapor, was passed over the surface of the solution.
- the Glee program P. Gans, B.
- Spectrophotometric titration of the Fe(III) complexes with flavone BJ486K as a function of pH was performed. Due to Fe(III)-catalyzed oxidation of BJ486K under neutral conditions, a specific protocol was adopted. A stock solution of BJ486K was freshly prepared by quantitative dissolution of a solid sample in CH 3 OH/H 2 O (80/20 by weight), which was further diluted to get a ligand concentration of 4.55 ⁇ 10 -5 M. The ionic strength was adjusted to 0.1 M with NEt 4 ClO 4 (Fluka, puriss).
- the ionic strength was adjusted to 0.1 M with tetraethylammonium perchlorate (Et 4 NClO 4 , Fluka, puriss.).
- the iron(III):BJ486K(:NTA) complex solutions were prepared as follows. Stock solutions were prepared and 200 ⁇ L of each solution was used:
- Coordination of Mg(II) by the ⁇ -hydroxy-ketone bidentate site of BJ486K induced a bathochromic shift of the band II which apparently tends to blend with band I as well as formation of the new band in the visible region of much lower intensity.
- the spectroscopic signatures are unambiguous features of BJ486K (XM148) metal coordination processes.
- thermodynamic parameters of BJ486K/MgCl 2 then allowed us to simulate the experimental conditions of a potential one-pot reaction (deprotection/complexation) of XM131 (the final precursor of BJ486K) with MgCl 2 ( Figure 19 ).
- Magnesium stearate melts at about 120 °C, is not soluble in water, and is generally considered safe for human consumption at levels below 2500 mg/kg per day. Magnesium stearate is also often used as an excipient in the manufacture of medical tablets, capsules and powders and might significantly decrease the release time of the active ingredients in tablets, which would significantly increase the rather low bio-availability of BJ486K (t 1/2 ⁇ 7 min in mice).
- stearic acids are used as auxiliary ligands.
- Distribution diagrams calculated for the ternary Mg(stearate) 2 : BJ486K complex allowed the evaluation of the amount of the magnesium(II) complex (93%) in solution ( Figure 21 ).
- Cremophor EL (from BASF) in mixture with DMSO was used to solubilize the XM148 -Mg-Stearate complex ( XM150 ).
- the protocol for solubilizing is as followed: Prepare 10 mM solution of XM150 in pure cremophor EL , then dilute to 1 ⁇ 2 with pure DMSO and let the sample at 60 °C in a rotative incubator (slow stirring) overnight. The day of the experiment, aqueous saline phosphate buffer (PBS) maintained at 60 °C was added, and the homogeneous solution was slowly diluted in a rotative incubator to final 1 mM of XM150 in aqueous PBS.
- PBS saline phosphate buffer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to flavone derivatives or compositions for use in the treatment and/or prevention of a viral infection.
- Various flavonoids, methods to obtain them and their uses, e.g. to treat infectious conditions such as viral or parasite infections, are known in the art and have been widely reported in the literature. For instance,
WO 01/03681 - Gupta et al, Bioorganic & Medical Chemistry Letters June 20, 2010, 4779-4781 discloses flavonoids as inhibitors of Plasmodium falciparum. However Gupta et al., does not suggest the use of the said flavonoids as antiviral compounds.
- Viruses are infectious agents that are found in virtually all life forms, including humans, animals, plants, fungi, and bacteria. Viruses often damage or kill the cells that they infect, causing disease in infected organisms. The difficulty in treating virus infections stems from the large number of variant viruses that can cause the same disease, as well as the inability of many drugs to disable a virus without disabling healthy cells.
- Interestingly, the entry mechanisms are shared or reasonably conserved between enveloped virus particles, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses. That is, virus-cell fusion is mediated by viral fusion proteins operating through shared mechanisms among enveloped viruses and modulating membrane properties of host and viral membranes.
- The Flaviviridae (also referred to as flaviviruses) are a family of viruses that infect a wide range of vertebrates and are spread through arthropods, mainly ticks and mosquitoes, or are transmitted parenterally (through blood) as well as sexually and vertically (from mother to child). The family Flaviviridae comprises three genera: Genus Flavi, Genus Hepaci, and Genus Pesti.
- The genus Flavi, for example, includes the species Dengue Virus 1-4; West Nile Virus; Yellow Fever Virus; Tick-borne Encephalitis Virus; Japanese Encephalitis Virus; St. Louis Encephalitis Virus; Murray Valley Encephalitis Virus; Kunjin Encephalitis Virus; Rocio Encephalitis Virus; Russian Spring Summer Encephalitis Virus; Negeishi Virus; Kyasanur Forest Virus; Omsk Hemorrhagic Fever Virus; Powassan Virus; Louping Ill Virus; Rio Bravo Virus 1-7; Tyuleniy Virus; Ntaya Virus; Uganda S Virus/Zika Virus; and Modoc Virus.
- The genus Hepaci includes the species Hepatitis C Virus and Hepatitis G Virus.
- The genus Pesti contains viruses infecting non-human mammals, e. g. Bovine virus diarrhea 1-3.
- The Flaviviruses are small (about 40 - 60 nm in diameter), enveloped, single-stranded RNA viruses with linear non-segmented genomes. The Flaviviridae genome is infectious and on average about 9.6 to 12.3 kilobase in length - it encodes around 10 genes. Viruses in this family are considered positive (+) sense because proteins are made directly from the template strand of RNA which is present in the viral capsid.
- Major diseases caused by the Flaviviridae family include: Hepatitis C Virus Infection; Dengue fever; encephalitis; and hemorrhagic fever.
- An overview on flaviviruses can, for example, be found in Westaway EG, et al.,"Flaviviridae", Intervirology 1985; 24(4): 183-92; Chambers TJ and Rice CM, "Molecular biology of the flaviviruses", Microbiol Sci. 1987; 4(7): 219-23; and Knipe DM and Peter MH, eds. Fields Virology; 5th ed. Vol. 2; Philidelphia, PA: Wolters Kluwer Health, 2007; p. 1102-1291.
- HIV is a retrovirus. Two types of HIV have been characterized: HIV-1 and HIV-2, which share a common structure. HIV is roughly spherical with a diameter of about 120 nm. It is composed of two copies of positive single-stranded RNA that codes for the virus's nine genes enclosed by a conical capsid composed of 2,000 copies of the viral protein p24, which is surrounded by a matrix composed of the viral protein p17 thereby ensuring the integrity of the virion particle and the viral envelope. The viral envelope contains a glycoprotein complex, which enables the virus to attach to and fuse with target cells to initiate the infectious cycle. That is, HIV infects macrophages, CD4+ T cells, and dendritic cells of the host by the adsorption of glycoproteins on its surface to receptors on the target cell followed by fusion of the viral envelope with the cell membrane and the release of the HIV capsid into the cell.
- The Herpesviridae (also referred to as herpesviruses) are a large family of DNA viruses that cause diseases in animals, including humans. Herpesviridae can cause infections, such as oral and/or genital herpes, chickenpox and shingles, infectious mononucleosis, Burkitt's lymphoma, CNS lymphoma, retinitis, sixth disease etc. Herpesviruses all share a common structure. The virus particle is composed of relatively large double-stranded, linear DNA genomes encoding 100-200 genes encased within a protein cage (called capsid), which is itself wrapped in a protein layer containing both viral proteins and viral mRNAs and a lipid bilayer membrane called the envelope. All herpesviruses are nuclear-replicating, i.e. the viral DNA is transcribed to RNA within the infected cell's nucleus. Infection is initiated when a viral particle contacts a cell with specific types of receptor molecules on the cell surface. Following binding of viral envelope glycoproteins to cell membrane receptors, the viral particle is internalized and dismantled, allowing viral DNA to migrate to the cell nucleus.
- VSV is a member of the family Rhabdoviridae, genus Vesiculovirus. It is a small, compact virus, with only 11-12 kilobases in its genome. The virus carries as its genome a single-stranded, minus sense RNA. In order for the virus to replicate, it must use its own polymerase to create mRNAs and then translate those into proteins. Infected hosts usually show flu-like symptoms, e.g. fever.
- The Orthomyxoviridae (also referred to as influenzaviruses) are a family of RNA viruses that includes five genera: influenzavirus A, influenzavirus B, influenzavirus C, isavirus and thogotovirus. Influenzavirus A, influenzavirus B, influenzavirus C and thogotoviruses cause influenza in vertebrats, including humans. Isaviruses infect salmon. Viruses of this family contain 6 to 8 segments of linear negative-sense single stranded RNA. The total genome length is 12000-15000 nucleotides. The viruses of this family are very similar in structure and the envelope can occur in spherical and filamentous forms. In general, the virus's morphology is spherical with particles (virions) 50 to 120 nm in diameter, or
filamentous virions 20 nm in diameter and 200 to 300 (-3000) nm long. - Although a number of drugs and methods exist or are currently under development for the treatment of viral infections, many of these are complicated by the side effects the anti-viral drug(s) has/have on the patient. Moreover, many of the known flavonoids have stability problems (oxidation, significant and rapid metabolism and conjugation during absorption in the body, poor bioavailability in the blood plasma) hampering their possible application as drugs (Jeremy P. E. Spencer, Metabolism of Tea Flavonoids in the Gastrointestinal Tract, J. Nutr. October 1, 2003 vol. 133 no. 10 3255S-3261S; C. Manach et al., Polyphenols: food sources and bioavailability, Am J Clin Nutr 2004;79:727-47). Additionally, drug-resistance and viral genotype-specific efficacy of these drugs necessitate alternative antiviral treatment options. Therefore, new therapeutics that eliminate chronic virus replication, prevent progression of the viral disease and/or preclude reinfection of the host are needed.
- It is, therefore, an aim of the present invention to provide novel antiviral compounds that are preferably inhibitors of virus entry, preferably of enveloped viruses, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses. Additionally, the invention relates to compositions for use in the treatment and/or prevention of a viral infection.
- The present invention was made in view of the prior art and the needs described above, and, therefore, the object of the present invention is to provide novel alternative means for treating and/or preventing viral infections, preferably viral infections with enveloped viruses, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses.
- Other objects of the present invention are to provide a pharmaceutical composition for use in the treatment and/or prevention of viral infections, preferably infections with enveloped viruses, to provide a combinatorial composition, comprising compounds for treating such viral infections.
- These objects are solved by the subject matter of the attached claims.
- These and other aspects of the present invention will become apparent upon reference to the following detailed description and definitions.
- The inventors established that certain compounds prevent virus life cycle steps, e.g. HCV, VSV and HIV-1 life cycle steps, subsequent to virus binding and prior to viral RNA translation and RNA replication. The inventors showed that combined administration of certain compounds and cyclosporine A had a synergistic effect in inhibition of HCV infection.
- The present description discloses a compound of the general formula (I):
A is: - n is an integer of 1 to 3;
- Ra and Rb each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an aryl, a C1-C6 alkyl or a C1-C6 alkoxy group;
- Rc and Rd each and independently of each other represent a hydrogen atom, halogen atom, an aryl, a C1-C6 alkyl or a C1-C6 alkoxy group;
- Re represents a hydrogen atom, halogen atom, an aryl or a C1-C6 alkyl group;
- R and R' each and independently of each other represent a hydrogen atom, a C1-C6 alkyl, or a C2-C6 alkenyl group;
- Ma is a non electroactive metal ion under its divalent state such as zinc, magnesium, calcium;
or - R1 is a group OR5 and R2 is an oxygen atom that is taken together with the β-carbonyl unit to form a metal complex of the general formula (II):
- Mb is a non electroactive metal ion under its divalent state such as zinc, magnesium, calcium, copper, or trivalent iron; and
- R5 is a hydrogen atom or an acetyl group;
- R3 is a C1-C6 alkyl or a C1-C6 alkoxy group;
- R4 is a nitro, cyano, sulphur pentafluoride, -SO3H, -SO2NH2, an optionally substituted C1-C6 alkyl or an optionally substituted C1-C6 alkoxy group, which may be substituted with one or more fluorine, chlorine, bromine or iodine atoms or by -OH, =O, -SH, =S, NH2, =NH or -NO2 group(s); and
- Z1, Z2, Z3, and Z4, each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group.
- The present invention is directed to a compound of the general formula (I):
A is: - Mb is a non electroactive metal ion under its divalent state such as zinc, magnesium, calcium, copper, or trivalent iron; and
- R5 is a hydrogen atom or an acetyl group;
- R3 is a C1-C6 alkyl or a C1-C6 alkoxy group;
- R4 is a nitro, cyano, sulphur pentafluoride, -SO3H, -SO2NH2, an optionally substituted C1-C6 alkyl or an optionally substituted C1-C6 alkoxy group, which may be substituted with one or more fluorine, chlorine, bromine or iodine atoms or by -OH, =O, -SH, =S, NH2, =NH or -NO2 group(s); and
- Z1, Z2, Z3, and Z4, each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group,
- Compounds are generally described herein using standard nomenclature, unless otherwise specified, and may be obtained according to methods described in the literature (e.g. Flavone synthesis: Maiti, A.; Cuendet, M.; Kondratyuk, T.; Croy, V. L.; Pezzuto, J. M.; Cushman, M. Synthesis and Cancer Chemopreventive Activity of Zapotin, a Natural Product from Casimiroa edulis. J. Med. Chem. 2007, 50, 350-355; Elbs oxidation for synthesis of the starting material 1: Elbs K. Ueber Nitrohydrochinon. J. Prakt. Chem. 1893, 48, 179-185; Methylenation of catechol : A.P. Bashall and J.F. Collin, Tetrahedron Lett. 1975, No. 40, 3489-3490; Silyl protection of catechol : Y. Chung, B. F. Duerr, T. A. McKelvey, P. Nanjappan, A. W. Czarnik J. Org Chem. 1989, 54, 1018-1032; Acetonide formation from catechol: M. Node, M. Ozeki, L. Planas, M. Nakano, H. Takita, D. Mori, S. Tamatani, T. Kajimotoor J. Org Chem. 2010, 75, 190-196; Phenyl ketal formation from catechol: S. R. K. Pingali, B. S. Jursic Tetrahedron Lett. 2011, 52, 4371-4374; O,O,O-orthoester formation from catechol: Gross, H.; Rusche, J. Chemische Berichte, 1966, 99, 2625-30; O,O,N-orthoester formation from catechol: Sokolova, E. A.; Maretina, I. A.; Petrov, A. A. Zhurnal Organicheskoi Khimii, 23(10), 2097-100; 1987; Carbonate from catechol: Hwu, Jih Ru; Hsu, Ming-Hua; Huang, Ru Chih C. Bioorg. Med. Chem. Lett. 2008, 18, 1884-1888; Sulfate from catechol: G. E. DuBois and R. A. Stephenson J. Org Chem. 1980, 45, 5371-5373; Sulfite from catechol: A. Adejare, D. D. Miller, J. S. Fedyna, C.-H Ahn, D. R. Feller J. Med. Chem. 1986, 29, 1603-1609; D. Malešev, V. Kunti, Investigation of metal-flavonoid chelates and the determination of flavonoids via metal-flavonoid complexing reactions, J. Serb. Chem. Soc. 72 (10) 921-939 (2007); Roshal A.D., Grigorovich A.V., Doroshenko A.O., Pivovarenko V.G., Demchenko A.P. Flavonols as metal-ion chelators: complex formation with Mg2+ and Ba2+ cations in the excited state. J. Photochem. Photobiol. A: Chem. 1999, 127, 89-100)
- For compounds having asymmetric centers, it should be understood that, unless otherwise specified, all of the optical isomers and mixtures thereof are encompassed. Compounds with two or more asymmetric elements can also be present as mixtures of diastereoisomers. In addition, compounds with carbon-carbon double bonds may occur in Z- and E- forms, with all isomeric forms of the compounds being included in the present invention unless otherwise specified. Where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather encompasses all tautomeric forms. Recited compounds further encompass compounds in which one or more atoms are replaced with an isotope, i.e., an atom having the same atomic number but a different mass number. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11C, 13C, and 14C.
- Compounds according to the formulas provided herein, which have one or more stereogenic center(s), have an enantiomeric excess of at least 50%. For example, such compounds may have an enantiomeric excess of at least 60%, 70%, 80%, 85%, 90%, 95%, or 98%. Some embodiments of the compounds have an enantiomeric excess of at least 99%. It will be apparent that single enantiomers (optically active forms) can be obtained by asymmetric synthesis, synthesis from optically pure precursors or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral HPLC column.
- Compounds herein may also be described using a general formula that includes variables such as, e.g. R1-R4, Ra-Re, Z1-Z4, Ma, Mb etc. Unless otherwise specified, each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently of each occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R*, the group may be unsubstituted or substituted with up to two R* groups and R* at each occurrence is selected independently from the definition of R*. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds, i.e. compounds that can be isolated, characterized and tested for biological activity.
- A "pharmaceutically acceptable salt" of a compound disclosed herein preferably is an acid or base salt that is generally considered in the art to be suitable for use in contact with the tissues of human beings or animals without excessive toxicity or carcinogenicity, and preferably without irritation, allergic response, or other problem or complication. Such salts include inorganic and organic acid salts of basic residues such as amines or pyridines, as well as alkali or organic salts of acidic residues such as carboxylic acids or basic residues such as phenols or catechols, thiophenols.
- Suitable pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzene sulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenylacetic, alkanoic such as acetic, HOOC-(CH2)n-COOH where n is any integer from 0 to 4, i.e., 0, 1, 2, 3, or 4, and the like. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, zinc, magnesium, lithium and ammonium. Those of ordinary skill in the art will recognize further pharmaceutically acceptable salts for the compounds provided herein. In general, a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally, the use of non-aqueous media, such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile, is preferred.
- It will be apparent that each compound of formula (I) may, but need not, be present as a hydrate, solvate or non-covalent complex. In addition, the various crystal forms and polymorphs are within the scope of the present invention.
- A "substituent," as used herein, refers to a molecular moiety that is covalently bonded to an atom within a molecule of interest, e.g. to a compound of formula (I) or a prodrug thereof. For example, a "ring substituent" may be a moiety such as a halogen atom, alkyl group, haloalkyl group or other substituent described herein that is covalently bonded to an atom, preferably a carbon or nitrogen atom, that is a ring member. The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound, i.e., a compound that can be isolated, characterized and tested for biological activity. When a substituent is oxo, i.e., =O, then 2 hydrogens on the atom are replaced. An oxo group that is a substituent of an aromatic carbon atom results in a conversion of -CH- to -C(=O)- and a loss of aromaticity. For example a pyridyl group substituted by oxo is a pyridone.
- The expression alkyl preferably refers to a saturated, straight-chain or branched hydrocarbon group that contains from 1 to 20 carbon atoms, preferably from 1 to 12 carbon atoms, more preferably from 1 to 6 carbon atoms, for example a methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, 2,2-dimethylbutyl, n-octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, or dodecyl group.
- The expressions alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 20 carbon atoms, preferably from 2 to 12 carbon atoms, more preferably from 2 to 6 carbon atoms, for example an ethenyl, allyl, acetylenyl, propargyl, isoprenyl or hex-2-enyl group. Preferably, alkenyl groups have one or two, more preferably one, double bond(s) and alkynyl groups have one or two, more preferably one, triple bond(s).
- The expression heteroalkyl preferably refers to an alkyl, alkenyl or alkynyl group, for example heteroalkenyl, heteroalkynyl, in which one or more, preferably 1, 2 or 3 carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulphur atom, preferably oxygen, sulphur or nitrogen. The expression heteroalkyl, for example, encompasses an alkoxy group. An alkoxy group denotes an alkyl group linked to oxygen thus: -O-alkyl. Furthermore, heteroalkyl preferably refers to a carboxylic acid or to a group derived from a carboxylic acid such as, for example, acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide, alkylcarbamoylalkyl, alkylcarbamoyloxyalkyl, alkylureidoalkyl, or alkoxycarbonyloxy.
- Examples of heteroalkyl groups are groups of formulas -S-Ya'-L, -S-Ya'-CO-NRa'Rb', -Ya'-NRc'-CO-NRa'Rb', -Ya'-NRc'-CO-O-Rd', -Ya'-NRc'-CO-Rd', -Ya'-NRc'-CO-NRd'-L, -Ya'-NRc'-CS-NRd'-L, -Ya'-O-CO-NRa'Rb', -Ya'-CO-NRa'Rb', -O-Ya'-CO-NRa'Rb', -Ya'-NRc'-CO-L, -Ya'-O-CO-O-Rc'. -Ya'-O-CO-Rc', -Ya'-O-Rc', -Ya'-CO-L, -Ya'-NRa'Rb', Rc'-S-Ya'-, Ra'-N(Rb')-Ya'-, Rc'-CO-Ya'-, Rc'-O-CO-Ya'-, Rc'-CO-O-Ya'-, Rc'-CO-N(Rb')-Ya'-, Ra'-N(Rb')-CO-Ya'-, Rc'-SO-Ya'-, Rc'-SO2-Ya'-, -Ya'-NRc'-SO2-NRa'Rb', -Ya'-SO2-NRa'Rb', -Ya'-NRc'-SO2-Rd', Ra'-O-CO-N(Rb')-Ya'-, Ra'-N(Rb')-C(=NRd')-N(Rc')-Ya'-, Rc'-S-CO-Ya'-, Rc'-CO-S-Ya'-, Rc'-S-CO-N(Rb')-Ya'-, Ra'-N(Rb')-CO-S-Ya'-, Rc'-S-CO-O-Ya'-, Rc'-O-CO-S-Ya'-, Rc'-S-CO-S-Ya'-; wherein Ra' being a hydrogen atom, a C1-C6alkyl, a C2-C6alkenyl, a C2-C6alkynyl , or is joined to Rb' to form a 4- to 10-membered cycloalkyl or heterocycloalkyl; Rb' being a hydrogen atom, a C1-C6alkyl, a C2-C6alkenyl or a C2-C6alkynyl , or taken together with Ra' to form a 4- to 10-membered cycloalkyl or heterocycloalkyl; Rc' being a hydrogen atom, an optionally substituted C1-C8alkyl, an optionally substituted C2-C8alkenyl or an optionally substituted C2-C8alkynyl ; Rd' being a hydrogen atom, optionally substituted C1-C8alkyl, optionally substituted C2-C8alkenyl or optionally substituted C2-C8alkynyl; L being a cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, aralkyl, or heteroaralkyl; and Ya' being a bond, a C1-C6alkylene, a C2-C6alkenylene or a C2-C6alkynylene group. Specific examples of heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, methoxyethyl, methyl amino, ethylamino, dimethylamino, diethylamino, isopropylethylamino, methylaminomethyl, ethylaminomethyl, diisopropylaminoethyl, enol ether, dimethylaminomethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxycarbonyl, isobutyrylamino-methyl, N-ethyl-N-methylcarbamoyl and N-methylcarbamoyl. Further examples of heteroalkyl groups are nitrile, isonitrile, cyanate, thiocyanate, isocyanate, isothiocyanate and alkylnitrile groups. An example of a heteroalkylene group is a group of formulas -CH2CH(OH)- or -CONH-.
- The expression cycloalkyl preferably refers to a saturated or partially unsaturated cyclic group that contains one or more rings, preferably 1 or 2, containing from 3 to 14 ring carbon atoms, preferably from 3 to 10, more preferably 3, 4, 5, 6 or 7, ring carbon atoms. In an embodiment a partially unsaturated cyclic group has one, two or more double bonds, such as a cycloalkenyl group. Examples of a cycloalkyl group are a cyclopropyl, cyclobutyl, cyclopentyl, spiro[4,5]decanyl, norbornyl, cyclohexyl, cyclopentenyl, cyclohexadienyl, decalinyl, bicyclo[4.3.0]nonyl, tetralin, cyclopentylcyclohexyl, fluorocyclohexyl or cyclohex-2-enyl group.
- The expression heterocycloalkyl preferably refers to a cycloalkyl group as defined above in which one or more, preferably 1, 2 or 3, ring carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom, preferably oxygen, sulphur or nitrogen. A heterocycloalkyl group has preferably 1 or 2 ring(s) containing from 3 to 10, more preferably 3, 4, 5, 6 or 7, ring atoms. Examples are a piperidyl, piperazinyl, morpholinyl, urotropinyl, pyrrolidinyl, tetrahydro-thiophenyl, tetrahydropyranyl, tetrahydrofuryl or 2-pyrazolinyl group and also a lactam, a lactone, a cyclic imide and a cyclic anhydride.
- The expression alkylcycloalkyl preferably refers to a group containing both cycloalkyl and also an alkyl, alkenyl or alkynyl group in accordance with the above definitions, for example alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkynylcycloalkyl groups. An alkylcycloalkyl group preferably contains a cycloalkyl group that contains one or two ring systems having from 3 to 10, preferably 3, 4, 5, 6 or 7, carbon atoms, and one or two alkyl, alkenyl or alkynyl groups having 1 or 2 to 6 carbon atoms, the cyclic groups being optionally substituted.
- The expression heteroalkylcycloalkyl preferably refers to alkylcycloalkyl groups as defined above in which one or more, preferably 1, 2 or 3, carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom, preferably oxygen, sulphur or nitrogen. A heteroalkylcycloalkyl group preferably contains 1 or 2 ring systems having from 3 to 10, preferably 3, 4, 5, 6 or 7, ring atoms, and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups having from 1 or 2 to 6 carbon atoms. Examples of such groups are alkylheterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkenyl, alkenylheterocycloalkyl, alkynylheterocycloalkyl, heteroalkylcycloalkyl, heteroalkylheterocycloalkyl and heteroalkylheterocycloalkenyl, the cyclic groups being optionally substituted and saturated or mono-, di- or tri-unsaturated.
- The expression aryl or Ar preferably refers to an aromatic group that contains one or more rings containing from 6 to 14 ring carbon atoms, preferably from 6 to 10, more preferably 6, ring carbon atoms. Examples are a phenyl, naphthyl, biphenyl, or anilinyl group.
- The expression heteroaryl preferably refers to an aromatic group that contains one or more rings containing from 5 to 14 ring atoms, preferably from 5 to 10, more preferably 5 or 6, ring atoms, and contains one or more, preferably 1, 2, 3 or 4, oxygen, nitrogen, phosphorus or sulphur ring atoms, preferably O, S or N. Examples are 4-pyridyl, 2-imidazolyl, 3-phenylpyrrolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl, pyridazinyl, quinolinyl, purinyl, carbazolyl, acridinyl, pyrimidyl, 2,3'-bifuryl, 3-pyrazolyl and isoquinolinyl.
- The expression aralkyl preferably refers to a group containing both aryl and also alkyl, alkenyl, alkynyl and/or cycloalkyl groups in accordance with the above definitions, such as, for example, arylalkyl, arylalkenyl, arylalkynyl, arylcycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups. Specific examples of aralkyls are toluene, xylene, mesitylene, styrene, benzyl, 1H-indene, tetralin, dihydronaphthalene, phenylcyclopentyl, cumene, cyclohexylphenyl, fluorene and indan. An aralkyl group preferably contains one or two aromatic ring systems, 1 or 2 rings, containing from 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing from 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms.
- The expression heteroaralkyl preferably refers to an aralkyl group as defined above in which one or more, preferably 1, 2, 3 or 4, carbon atoms have been replaced each independently of the others by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or sulphur atom, preferably oxygen, sulphur or nitrogen, that is to say to groups containing both aryl or heteroaryl and also alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cycloalkyl and/or heterocycloalkyl groups in accordance with the above definitions. A heteroaralkyl group preferably contains one or two aromatic ring systems, 1 or 2 rings, containing from 5 or 6 to 10 ring carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms, 1, 2, 3 or 4 of those carbon atoms having been replaced each independently of the others by oxygen, sulphur or nitrogen atoms.
- Examples of heteroaralkyl groups are aryloxy, arylheteroalkyl, arylheterocycloalkyl, arylheterocyclo-alkenyl, arylalkylheterocycloalkyl, arylalkenylheterocycloalkyl, arylalkynylheterocycloalkyl, arylalkyl-heterocycloalkenyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroarylheteroalkyl, hetero-arylcycloalkyl, heteroarylcycloalkenyl, heteroarylheterocycloalkyl, heteroarylheterocycloalkenyl, hetero-arylalkylcycloalkyl, heteroarylalkylheterocycloalkenyl, heteroarylheteroalkylcycloalkyl, heteroarylhetero-alkylcycloalkenyl, heteroalkylheteroarylalkyl and heteroarylheteroalkylheterocycloalkyl groups, the cyclic groups being saturated or mono-, di- or tri-unsaturated. Specific examples are a tetrahydroisoquinolinyl, benzoyl, 2- or 3-ethylindolyl, 4-methylpyridino, 2-, 3- or 4-methoxyphenyl, 4-ethoxyphenyl, 2-, 3- or 4-carboxyphenylalkyl group.
- The expression "substituted" or "optionally substituted" as used herein in connection with any group refers to a group in which one or more hydrogen atoms have been replaced each independently of the others by fluorine, chlorine, bromine or iodine atoms or by -OH, =O, -SH, =S, -NH2, =NH, -CN or -NO2 group(s). Examples of substituted alkyl are 2,2,2-trichloroethyl or trifluoromethyl, and examples of substituted aryl (or substituted Ar) are 2-fluorophenyl, 3-nitrophenyl or 4-hydroxyphenyl.
- The expression "halogen" or "halogen atom" as preferably used herein means fluorine, chlorine, bromine, iodine.
- As used herein a wording defining the limits of a range of length such as, e. g., "from 1 to 5" means any integer from 1 to 5, i. e. 1, 2, 3, 4 and 5. In other words, any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.
-
- n is an integer of 1 to 3;
- Ma represents Ca2+, Zn2+, or Mg2+;
- Ra and Rb each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an aryl, a C1-C6 alkyl or a C1-C6 alkoxy group;
- Rc and Rd each and independently of each other represent a hydrogen atom, halogen atom, an aryl, a C1-C6 alkyl or a C1-C6 alkoxy group;
- Re represents a hydrogen atom, halogen atom, an aryl or a C1-C6 alkyl group;
- R' and R" each and independently of each other represent a hydrogen atom, a C1-C6 alkyl, or a C2-C6 alkenyl group;
- R3 is a C1-C6 alkyl or a C1-C6 alkoxy group;
- R4 is a nitro, cyano, sulphur pentafluoride, -SO3H, -SO2NH2, an optionally substituted C1-C6 alkyl or an optionally substituted C1-C6 alkoxy group, which may be substituted with one or more fluorine, chlorine, bromine or iodine atoms or by -OH, =O, -SH, =S, NH2, =NH or -NO2 group(s); and
- Z1, Z2, Z3, and Z4, each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group.
-
-
-
-
- Preferably, in the compounds of the present invention, R4 is OMe, CF3, OCF3, fluorine, chlorine, bromine, or -SO3H. Further preferred, R4 is OMe, CF3, or OCF3.
- Further preferably, in the compounds of the present invention, R3 is methyl or OMe, more preferably OMe.
- Further preferably, in the compounds of the present invention, Z1 to Z4 are each and independently selected from hydrogen atom, fluorine, chlorine, bromine, and C3-C6 alkyl. Preferably, all of Z1 to Z4 represent hydrogen atoms.
- Preferably, in the present description, Ra, Rb, Rc, Rd, and Re each and independently of each other represent a hydrogen atom, an aryl or a C1-C6 alkyl group. Further preferred, Ra, Rb, Rc, Rd, and Re are each and independently of each other hydrogen atom or a C1-C6 alkyl group.
- The therapeutic use of compounds of general formula (I) or (II), their pharmacologically acceptable salts or solvates and hydrates also lie within the scope of the present invention, especially, their use as antiviral agents, especially for the treatment and/or prevention of an infection by an enveloped virus, such as flaviviruses (e.g. hepatitis C virus (HCV), dengue virus, west nile virus), human immunodeficiency virus (HIV), herpesviruses, vesicular stomatitis virus (VSV), or influenza viruses, particularly the treatment of hepatitis C.
-
- The present invention also relates to a pharmaceutical composition comprising at least one above-mentioned compound, and, optionally, at least one pharmaceutically acceptable carrier(s) and/or at least one customary excipient.
- Preferably, the pharmaceutical composition of the invention comprises at least one compound selected from:
or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. - Preferably, the compound used for the prevention and/or treatment of a viral infection is a compound according to general formula (I), (II), or a compound selected from:
or is selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. -
- According to the invention, it is also possible to use a combination of compounds according to the invention.
- The invention is also directed to the use of a compound according to general formula (I) or (II) for the preparation of a medicament intended for the prevention and/or treatment of a viral infection, preferably a viral infection by enveloped virus particles.
- The invention also relates to an above-mentioned compound for use in the prevention and/or treatment of a viral infection, wherein the infection is an infection by an enveloped virus.
- Moreover, the description is also directed to a pharmaceutical composition for use in the treatment and/or prevention of a viral infection, preferably a viral infection by enveloped virus particles, which pharmaceutical composition comprises at least one compounds according to general formula (I), (II), or a compound selected from:
- By "treatment and/or prevention" is preferably meant a reduction or complete inhibiton of viral replication and/or infectivity in a subject to thereby cure or prevent the symptoms associated with the viral infection.
- By inhibitor is meant any chemical or biological, natural or synthetic molecule, any composition which, whatever the mechanism, causes after administration a reduction, or even a complete inhibition, of the activity of the respective protein or member of the protein family or the expression of the corresponding gene(s) thereof. An inhibitor may either bind reversible or irreversible to its substrate. Reversible inhibitors comprise competitive inhibitors, non-competitive inhibitors, mixed-type inhibitors, uncompetitive inhibitors, slow-binding or tight-binding inhibitors, transition state analogs and multi-substrate analogs. A compound of the present invention may also be referred to as virus life cycle inhibitor, i.e. a compound that hampers or suppresses the initial interactions between a virus and the host cell that are essential for any virus infection.
- The term "at least one" as used herein is intended to mean one, 2, or more of the respective item or subject.
- Carrier substances are, for example, cyclodextrins such as hydroxypropyl β-cyclodextrin, micelles or liposomes, excipients and/or adjuvants. Pharmaceutical compositions may additionally comprise, for example, one or more of water, buffers such as, e.g., neutral buffered saline or phosphate buffered saline, ethanol, propylene glycol, mineral oil, vegetable oil, dimethylsulfoxide, lipids, emulsifiers, carbohydrates such as e.g., glucose, mannose, sucrose or dextrans, mannitol, proteins, adjuvants, polypeptides or amino acids such as glycine, antioxidants, metal ions such as zinc(II), calcium(II) or magnesium(II) and/or preservatives. Furthermore, one or more other active ingredients may, but need not, be included in the pharmaceutical compositions provided herein. For instance, the compounds of the invention may advantageously be employed in combination with an antibiotic, anti-fungal, or anti-viral agent, an antihistamine, a non-steroidal anti-inflammatory drug, a disease modifying anti-rheumatic drug, a cytostatic drug, a drug with smooth muscle activity modulatory activity or mixtures of the aforementioned.
- S. Sholz, G. Williamson, Interactions Affecting the Bioavailability of Dietary Polyphenols in Vivo, Int. J. Vitam. Nutr. Res. 77, 2007, 224-235.
- Pharmaceutical compositions may be formulated for any appropriate route of administration, including, for example, topical such as, e.g., transdermal or ocular, oral, buccal, nasal, vaginal, rectal or parenteral administration. The term parenteral as used herein includes subcutaneous, intradermal, intravascular such as, e.g., intravenous, intramuscular, spinal, intracranial, intrathecal, intraocular, periocular, intraorbital, intrasynovial and intraperitoneal injection, as well as any similar injection or infusion technique. In certain embodiments, compositions in a form suitable for oral use are preferred. Such forms include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Within yet other embodiments, compositions provided herein may be formulated as a lyophilizate.
- Compositions intended for oral use may further comprise one or more components such as sweetening agents, flavoring agents, coloring agents and/or preserving agents in order to provide appealing and palatable preparations. Tablets contain the active ingredient in admixture with customary (physiologically acceptable) excipients that are suitable for the manufacture of tablets.
- Customary excipients include, for example, inert diluents such as, e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents such as, e.g., corn starch or alginic acid, binding agents such as, e.g., starch, gelatin or acacia, and lubricating agents such as, e.g., magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- The pharmaceutical composition of the invention may comprise at least one of the above virus life cycle inhibitors. The pharmaceutical composition may also comprise 2 or more of the above virus life cycle inhibitors.
- For the treatment and/or prevention of a viral infection, preferably an infection by an enveloped virus particle, the dose of the biologically active compound according to the invention may vary within wide limits and may be adjusted to individual requirements. Active compounds according to the present invention are generally administered in a therapeutically effective amount. Preferred doses range from about 0.1 mg to about 140 mg per kilogram of body weight per day, and/or about 5 mg to about 7 g per patient per day. The daily dose may be administered as a single dose or in a plurality of doses. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- According to the invention, the above virus life cycle inhibitor(s) can be used in the pharmaceutical preparation in a quantity comprised between 0.01 mg and 2 g, preferably from 1 mg to 1 g, very preferably from 10 mg to 500 mg.
- More particularly, the above virus life cycle inhibitor(s) can in particular be administered in doses comprised between 0.1 mg/kg and 500 mg/kg, preferably 1 mg/kg and 100 mg/kg, very preferably 10 mg/kg and 50 mg/kg.
- It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, i.e. other drugs being used to treat the patient, and the severity of the particular disease undergoing therapy.
- The invention is also related to a combination preparation containing at least one of the above virus life cycle inhibitors and at least one further active pharmaceutical ingredient for the treatment or prophylaxis of viral infections, such as an HCV, HIV, VSV, herpes or influenza infection.
- The present invention also relates to a combination preparation for use in the treatment or prophylaxis of a viral infection containing at least one above-mentioned compound, or the compound:
- The present invention also relates to a combination preparation for use in the treatment or prophylaxis of a viral infection containing at least one compound selected from:
or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. - Preferably, in the combination preparation of the invention the further active pharmaceutical ingredient is selected from cyclosporine A, pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, ribavirin, viramidine, boceprevir (Victrelis), telaprevir (Incivo),
SP 30, ITX 5061, RG7128, PSI-7977, NM 283, Albuferon and/or Zadaxin, most preferably cyclosporine A. - Moreover, it is preferred that the combination preparation of the invention contains at least one inhibitor of cPLA2. Most preferred is a combination of at least one cPLA2 inhibitor and at least one of pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, ribavirin and viramidine.
- Preferably, the above virus life cycle inhibitors used for the treatment of viral infections will have certain pharmacological properties. Such properties include, but are not limited to oral bioavailability, such that the preferred oral dosage forms discussed above can provide therapeutically effective levels of the compound in vivo.
- The above virus life cycle inhibitors are preferably administered to a patient orally or parenterally, and are present within at least one body fluid or tissue of the patient.
- Accordingly, the present disclosure further provides methods for preventing or treating patients suffering from a viral infection, especially an infection by an enveloped virus particle.
As used herein, the term "treatment" encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic, i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms, or therapeutic, i.e., after the onset of symptoms, in order to reduce the severity and/or duration of symptoms. - Preferably, the method of preventing or treating a viral infection according to the present disclosure comprises administering to a subject in need thereof an effective amount of at least one of the above virus life cycle inhibitors.
- In a preferred method of preventing or treating a HCV infection according to the present disclosure, the method comprises administration of at least one of the virus life cycle inhibitors detailed above for use in the prevention and/or treatment of HCV infection. More particularly, the method preferably comprises administration of at least one of the virus life cycle inhibitors:
- The method of preventing or treating a viral infection, e.g. HCV infection, according to the present disclosure may, moreover, be characterized in that the virus life cycle inhibitor is intended to be administered by oral route, by aerosol route or by injection.
- It is especially preferred to combine the preferred embodiments of the present invention in any possible manner.
-
-
Figure 1 : Antiviral activity of BJ486K. (A) Huh7-Lunet/CD81 cells were inoculated for 48h with Luc-Jc1 virus particles in the presence of increasing doses of BJ486K or MP03, respectively. HCV infection and replication efficiency was determined 48h post inoculation using luciferase assays and is expressed as % of cells treated with solvent alone. Mean values of three independent experiments each with quadruplicate measurements including the standard deviation are shown. (B) Huh7-Lunet/CD81 cells were cultured for 48h in the presence of increasing doses of BJ486K or MP03, respectively. Cell viability was determined using a commercial cytotoxicity assay (CytoToxGlo; Promega, Germany) and is expressed relative to cells treated with DMSO. Mean values of three independent experiments each with quadruplicate measurements including the standard deviation are shown. -
Figure 2 : BJ486K selectively inhibits HCV cell entry. (A) Huh7-Lunet/CD81 cells were transfected with the subgenomic luciferase replicon depicted at the top. Drugs were added 4h post transfection and the level of HCV RNA translation and RNA replication was quantified by luciferase assays 72h post transfection. Mean values of three independent experiments each with quadruplicate measurements including the standard deviation are shown. (B) Cells were transfected with the Jc1 chimera depicted above and drugs were added 4h later. HCV virus release in the presence or absence of given compounds was determined by quantification of intracellular and extracellular core protein levels using a core-specific ELISA. Mean values of three independent experiments with single measurements including the error range are given. (C) Huh7-Lunet/CD81 cells were inoculated with Luc-Jc1 reporter viruses prepared in the absence of drugs. BJ486K was added to the cells only prior to inoculation (black), only during inoculation (grey) or selectively directly after inoculation (white) as schematically depicted at the top. Infectivity was determined 72h later by luciferase assays and compared to DMSO-treated controls. Mean values of three independent experiments each with quadruplicate measurements including the standard deviation are shown. -
Figure 3 : BJ486K inhibits cell entry post virus attachment.
The design of the JcR-2a reporter virus construct is given at the top. Huh7-Lunet/CD81 cells were inoculated with concentrated JcR-2a particles at 4°C for 60 minutes. Subsequently, unbound virus particles were washed away and cells were shifted to 37°C to permit synchronized cell entry. According to the 8 experimental protocols depicted in the middle, various cell entry inhibitors including heparin (50 µg/ml), ITX5061 (10 µM), CD81-specific antibody JS-81 (2 µg/ml) and BJ486K (20 µM) were either present during inoculation (protocol 1) or were added at different time points after inoculation (protocols 2 to 8). In each case, inhibitor was present for 4h (dashed line) and was then washed away. Efficiency of cell entry was determined 48h post inoculation by determination of luciferase activity and is expressed relative to control infections conducted in the presence of solvent alone (DMSO). Mean values of three independent experiments each with quadruplicate measurements including the standard deviation are shown. -
Figure 4 : BJ486K is not affected by viral resistance towards a SR-BI-targeting compound, inhibits HCV of different genotypes and prevents infection of primary human hepatocytes Huh7-Lunet/CD81 cells were inoculated with Luc-Jc1 or Luc-Jc1/E2/G451R reporter viruses in the presence of increasing doses of (A) ITX 5061 or (B) BJ486K. Cells were lysed 72h later. Luciferase activity was determined and is expressed relative to control infections conducted in the presence of DMSO. Mean values of four independent experiments each with quadruplicate measurements including the standard deviation are shown. (C) Huh7-Lunet/CD81 cells were inoculated withgenotype -
Figure 5 : Combination of BJ486K and CsA prevents infection of differentiated human hepatoma cells. Huh7-Lunet/CD81 cells were differentiated by treatment with 1% DMSO as described recently (Sainz B et al., J. Virol. 2006; 80: 10253-10257). Subsequently cells were challenged with Jc1 in the presence of DMSO (A), CsA (B), BJ486K (C), or a combination of CsA and BJ486K (D). Culture fluids of the inoculated cells were collected at 3, 6, 9 and 12 days post inoculation and the infectivity of released virus particles was determined by a limiting dilution assay. -
Figure 6 : Synergistic antiviral activity of BJ486K and CsA. Combined effects of CsA on BJ486K and vice versa were analysed by inoculation of Huh7-Lunet/CD81 cells with JcR-2a virus in the presence of given drugs and determination of luciferase activity 72h later. Mean values of three independent experiments each conducted in triplicates including the standard deviations are given. Data are normalized for values determined in mock treated controls. -
Figure 7 : Antiviral activity of BJ486K on enveloped HIV virus. -
Figure 8 : Antiviral activity of BJ486K on enveloped and non-enveloped viruses. Influence of BJ486K on enveloped vesicular stomatitis viruses and non-enveloped group B coxsackievirus (CoxV) and adenovirus type 5 (AdV5); determined using limiting dilution assays. -
Figure 9 : Comparison offlavones 13, 14 and 15. Huh-7.5 cells were seeded in 12-well plates and infected for 4h with FF-Jc1 reporter virus +/- inhibitor (ranging from 0-100 µM final concentration). 72h after infection, the cells were lysed and the reporter activity measured. The mean values of 6 measurements are shown in the graph. Fluorine analogues of flavone 13, flavones 14 (BJ751/1) and 15 (BJ755-3 I), inhibit HCV cell entry with 8-10-fold increased effects compared to those of the flavone 13. Specifically, flavones 14 (BJ751/1) and 15 (BJ755-3 I) show an EC50 of about 300 nM and an IC90 of about 1 µM, while flavone 13 (BJ486K) shows an EC50 of about 2000 nM. -
Figure 10 : Oral bioavailability of BJ486K in mice. A single dose of 0.25mg/kg of BJ486K was administered through oral (A) or intravenous route (B). Plasma levels of BJ486K were determined 5, 15, 30, 60, 120 and 180 minutes post administration. Mean values of two animals including the standard errors are given. (C) -
Figure 11 : Additive antiviral activity of BJ486K and Chloroquine (CQ). (A) Treatment with chloroquine alone shows a dose-dependent inhibition of HCV (red bar), whereas no cytotoxicity (blue bar) could be observed at the used concentrations. Result from one experiment with triplicate measurements is given. (B) Combined effects of CQ on BJ486K activity (and vice versa) were analyzed by inoculation of Huh7.5 F-Luc cells with JcR-2a virus in the presence of given drugs and determination of luciferase activity 72h later. Results from 3 independent experiments are given. -
Figure 12 : Determination of BJ486K/Fe(III) complex stoichiometry - Job's plot. The stoichiometry of the BJ486K:Fe(III) complex was determined with the method of continuous variations (solvent: CH3OH/H2O (80/20 by weight); I = 0.1 M (NEt4ClO4); pH = 2.0; T = 25.0(2) °C; l = 1 cm; ([Fe(III)]tot + [BJ486K]tot) = 4.94 × 10-5 M). A series of solutions of MB and FeIIIPPIX at pH 2.0 subject to the condition that the sum of the total BJ486K and Fe(III) concentrations is constant (4.94 × 10-5 M) were prepared. Absorption spectra were measured for each of the solutions and the extremum xmax value (∼ 0.43) indicates the predominant formation of a 1:1 stoichiometry complex (BJ486K: Fe(III)). -
Figure 13 : Spectrophotometric titration of BJ486K with Fe(III) solution at pH 2.0. The absorption spectrophotometric titration of BJ486K by Fe(III) at pH 2.0 (solvent: CH3OH/H2O (80/20 by weight); I = 0.1 M (NEt4ClO4); T = 25.0(2) °C; pH = 2.0; 1 = 1 cm; (1) [BJ486K]tot = 5.92 × 10-5 M; (2) [Fe(III)]tot/[BJ486K]tot = 1.60) shows the ability of the flavone BJ486K to firmly bind Fe(III) through its β-hydroxy-ketone chelating unit. The Fe(III) coordination is evidenced by the formation of a BJ486K-to-Fe(III) charge transfer absorption band at 633 nm as typically observed for phenolate or catecholate Fe(III) binders ((a) D.D. Cox, S.J. Benkovic, L.M. Bloom, F.C. Bradley, M.J. Nelson, L. Que Jr., D.E. Wallick "Catecholate LMCT bands as probes for the active sites of nonheme iron oxygenases" J. Am. Chem. Soc. 1988, 110, 2026-2032. b) B.P. Gaber, V. Miskowski, T.G. Spiro "Resonance Raman scattering from iron(III)- and copper(II)-transferrin and an iron(III) model compound. Spectroscopic interpretation of the transferrin binding site" J. Am. Chem. Soc. 1974, 96, 6868-6873. c) M. Elhabiri, C. Carrër, F. Marmolle, H. Traboulsi "Complexation of iron(III) by catecholate-type polyphenols" Inorg. Chim. Acta 2007, 360, 353-359). The BJ486K:Fe(III) complex was characterized and quantified (log K * BJ486K:Fe = 6.0(3) at pH 2.0; K D 1µM). This BJ486K:Fe(III) complex possesses comparable stability as that determined for salvigenin: Fe(III) under identical experimental conditions (log K * salvigenin:Fe = 5.8(2) at pH 2.0; K D 1.6 µM). -
Figure 14 : Absorption spectrophotometric titration of the ferric complexes of BJ486K vs. pH. The absorption spectrophotometric titration of the BJ486K:Fe(III) complex versus pH (solvent: CH3OH/H2O (80/20 w/w); I = 0.1 M (NEt4ClO4); T = 25.0(2) °C; l = 1 cm ; [BJ486K]tot = 4.55 × 10-5 M ; [Fe(III)]tot = 4.14 × 10-5 M ; (1) pH = 1.72 ; (2) pH = 6.79.spectra vs. pH (1.72 < pH< 6.79) is shown inFig. 13A . The diagramme depicted inFig. 13B shows the distribution of the ferric complexes of BJ486K as a function of pH (solvent: CH3OH/H2O (80/20 w/w); I = 0.1 M (NEt4ClO4); T = 25.0(2) °C; [BJ486K]tot = [Fe(III)]tot = 5 × 10-5 M). Three protonated species of the monoferric monochelates with the flavone BJ486K were characterized and quantified on the basis of the spectral changes centered on the BJ486K-to-Fe(III) charge transfer absorption. At pH > 7, the fully deprotonated BJ486K:Fe(III) complex (log K BJ486K:Fe = 23.8(2)) is the predominant ferric species and the metal cation is monohydroxylated. The 6-hydroxyl unit (cycle A) is also deprotonated. This species undergoes two successive protonations. The first one concerns the hydroxyl ligand coordinated to the metal center (log K BJ486K:Fe(OH) = - 4.4(4)). The second one is related to the protonation of the 6-hydroxyl unit (log K BJ486K:Fe = 3.6(3)). -
Figure 15 : Spectrophotometric titration of BJ486K with FeNTA solution at pH = 7.4. The figure shows the results of an UV-visible absorption spectrophotometric titration of the flavone BJ486K by FeNTA at pH 7.4 (solvent: CH3OH/H2O (80/20 by weight); I = 0.1 M (NEt4ClO4); T = 25.0(2) °C; pH = 7.4 (hepes 0.1 M); l = 1 cm; (1) [BJ486K]tot = 5.41 x 10-5 M; (2) [FeNTA]tot/[BJ486K]tot= 2.0). A ternary BJ486K:Fe(III):NTA complex was characterized and quantified (log β * BJ486K:Fe:NTA = 10.7(4) at pH 7.4). NTA completes the Fe(III) sphere and prevents hydrolysis of the metal cation, the degradation by autooxidation is not taking the place and the titration can be performed continuously. The BJ486:Fe(III):NTA complex is characterized by the presence of a broad charge-transfer absorption centered at 580 nm with a molar extinction coefficient ε580 of 2220 M-1 cm-1. The presence of the NTA binder induces a hypsochromic shift of the charge-transfer band of about 53 nm with respect to the BJ486K:Fe(III) complex. -
Figure 16 : Antiviral activity of the free flavones BJ486K compared to the BJ486K:Fe(III) complex and to the BJ486K:Fe(III):NTA complex. Huh-7.5 cells were inoculated with F-LucJc1 reporter virus preincubated with the given amount of either BJ486K, BJ486K.Fe(III) complex or BJ486K: Fe(III):NTA complex for 4h at 37°C. 72h post infection, cells were lysed and firefly reporter activity was measured. Mean values of 4 single measurements within one experiment are shown. -
Figure 17 : (A) UV-visible spectrophotometric titration of BJ486K (newly re-prepared as XM148) by MgCl2 and (B) absorption electronic spectra of the flavone BJ486K and its magnesium(II) complex BJ486K-MgCl2. Solvent: CH3CN/H2O (1:1 by volume); T = 25.0 °C; l = 1 cm; [BJ486K]tot = 7.63 × 10-5 M; (1) [MgCl2]tot/[BJ486K]tot = 0; (2) [MgCl2]tot/[BJ486K]tot = 185.8. To ensure solubilisation of both the flavone BJ486K (newly re-prepared as XM148) and MgCl2, a mixed solvent made of 50% of water and 50% of CH3CN was used. A stock solution of XM148 (3.0 mg in 10 mL of argon saturated CH3CN, [XM148]tot = 9.54 × 10-3 M) was prepared. 160 µL of the flavone stock solution in CH3CN was diluted in 1 mL and 840 µL of Ar-saturated water and CH3CN, respectively. The absorption spectrophotometric titration (200 - 800 nm) was carried out by successive addition of aliquots (10 µL) of a stock solution of MgCl2 freshly prepared in water (337.6 mg in 5 mL, [MgCl2]tot = 7.09 × 10-3 M). The figure shows the corresponding absorption spectral data. Mg(II) complexation was clearly ascertained thanks to bathochromic shift of the band II of the flavone which blends with band I as well as the formation of the new band in the visible region of much lower intensity. The spectroscopic signatures are unambiguous features of BJ486K (XM148) metal coordination processes. Statistical processing of the spectral data allowed calculating the stability of the XM148-MgCl2 complex (log K = 2.4 ± 0.3) which is in good agreement with the very rare physico-chemical data available for flavone/Mg(II) complexes ((a) 2000LXa H Li,H Xie,P Wang,S Wu; New J.Chem.,24,105 (2000)) . -
Figure 18 : (A) UV-visible spectrophotometric titration of XM131 (final precursor B, Scheme 2) by MgCl2. Solvent: CH3CN/H2O (1:1 by volume); T = 25.0 °C; l = 1 cm; [XM131]tot = 7.13 × 10-5 M; (1) [MgCl2]tot/[XM131]tot = 0; (2) [MgCl2]tot/[XM131]tot = 99.4. To get further evidences of Mg(II) complexation by the flavone BJ486K (newly re-prepared as XM148), the final precursor B (noted XM131, the 5-OH protected BJ486K precursor) was titrated by MgCl2 under identical experimental conditions. 2.8 mg of XM131 was dissolved in 10 mL of Ar-saturated CH3CN ([XM131]tot = 8.53 × 10-4 M). An aliquot of 160 µL of the flavone stock solution was diluted in 840 µL + 1 mL of Ar-saturated CH3CN and water, respectively. Absorption spectra (200 - 800 nm) was recorded after each addition of aliquots (10 µL) of a stock solution of MgCl2 freshly prepared in water (337.6 mg in 5 mL, [MgCl2]tot = 7.09 × 10-3 M). The figure shows the corresponding absorption spectral data. As anticipated, no absorption variation can be observed even in the presence of high excess of Mg(II) with respect to the final precursor B (XM131). Together with the spectral and thermodynamic data obtained on ferric complexes with BJ486K and salvigenin, these spectroscopic data once again established that the β-hydroxy-ketone bidentate site of BJ486K is the active metal coordination site. -
Figure 19 : Distribution diagram of the Mg(II) complex formation with flavone BJ486K using chloride anion. Solvent: CH3CN/H2O (1:1 by volume); T = 25.0 °C. [BJ486K]tot = 0.016 M (equivalent to 40 mg of the flavone in 8 mL of CH3CN). To simulate the experimental conditions required to perform a one-pot reaction (deprotection/complexation) of XM131 (the final precursor of BJ486K) with MgCl2, a distribution diagram was calculated using the previously determined stability constant of the BJ486K-MgCl2 complex (log K = 2.4 ± 0.3). The concentration of BJ486K was fixed at 0.016 M, which corresponds to our standard experimental conditions for low scale preparation and the [MgCl2]/[BJ486K] ratio was varied from 0 to 6.25. The figure shows that a significant excess of MgCl2 is indeed required for the formation of more than 95% of magnesium(II) complex for [BJ486K]tot = 0.016 M. Using such strategy will certainly lead to formulations containing high excess of MgCl2, which might interfere with accurate determination of the flavone-MgCl2 complex content. -
Figure 20 : (A) UV-visible spectrophotometric titration of BJ486K by Mg(stearate)2 and (B) absorption electronic spectra of the flavone BJ486K and its magnesium(II) complex BJ486K-Mg(stearate)2. Solvent: dioxane; T = 25.0 °C; l = 1 cm; [BJ486K] = 1.52 × 10-5 M; (1) [Mg(stearate)2]/[BJ486K] = 0; (2) [Mg(stearate)2]/[BJ486K] = 13.26. To overcome the thermodynamic barrier experienced with the MgCl2 salt, we anticipated that the use of another magnesium(II) salt containing stabilizing auxiliary ligands such as stearic acid might favor complexation by the BJ486K flavone. To ensure adequate solubilisation of both the flavone BJ486K (newly re-prepared as XM148) and Mg(stearate)2, dioxane solvent was selected. A stock solution of BJ486K (1.6 mg in 5 mL of argon saturated dioxane, [XM148]tot = 1.02 × 10-3 M) was prepared. On the other side, 34.3 mg of Mg(stearate)2 was refluxed in 10 mL of dioxane under argon to ensure appropriate dissolution. An aliquot of 30 µL of the flavone stock solution in dioxane was diluted in 2 mL of Ar-saturated dioxane ([XM148]tot = 1.52 × 10-5 M). The absorption spectrophotometric titration (200 - 800 nm) was carried out by successive addition of aliquots (5 µL) of a stock solution of Mg(stearate)2 freshly prepared in dioxane. The figure shows the corresponding absorption spectral data. As previously observed with MgCl2 and XM148 in CH3CN/water solvent, Mg(II) complexation was clearly evidenced thanks to bathochromic shift of the band II of the flavone as well as the formation of the less intense absorption in the visible region. These spectroscopic signatures are once again unambiguous features of BJ486K (XM148) Mg(II) complexation. Statistical processing of the spectral data allowed calculating the stability of the XM148-Mg(stearate)2 complex (log K = 4.1 ± 0.6) which is, as anticipated, much higher than that calculated in the case of MgCl2 salt. These data are therefore strong proofs of our metal coordination strategy and show that Mg(II) can act as an anchor point to introduce, by adequate formulation, the flavone BJ486K and its analogs and a wide variety of auxiliary ligands (solubilizing and/or stabilizing groups, active molecules against enveloped viruses such as cyclosporine, chloroquine...) -
Figure 21 : Distribution diagram of the Mg(II) complex formation with flavone BJ486K using stearate auxiliary anion. Solvent: dioxane; T = 25.0 °C; [BJ486K] = 0.016 M (equivalent to 40 mg of the starting flavone in 8 mL of dioxane).
To further model the experimental conditions required to perform this formulation reaction using Mg(stearate)2 reactant, a distribution diagram was calculated using the calculated stability constant of the BJ486K-Mg(stearate)2 complex (log K = 4.1 ± 0.6). The concentration of BJ486K was fixed at 0.016 M, which corresponds to our standard experimental conditions for low scale preparation. The [Mg(stearate)2]/[BJ486K] ratio was varied from 0 to 1.25. The figure clearly shows that for a stoichiometric ratio [Mg(stearate)2] : [BJ486K] more than 93% of magnesium(II) complex is formed in solution. -
Figure 22 : IR spectra of Mg(II) stearate, BJ486K and of their complex Mg(II)/stearate/BJ486K. The figure shows the Infra Red spectrum recorded for the isolated BJ486K-Mg(stearate)2 complex compared to those of its starting reactants, namely BJ486K and Mg(stearate)2. These IR spectra show that the hydroxy stretching band appearing at 3157 cm-1 for the free flavone (5-OH) disappears completely once the flavone is complexed to the magnesium(II). Together with the numerous absorption data acquired in this physico-chemical investigation, this feature definitively assess that a chelation process has taken place and that the β-hydroxy-ketone bidentate site of BJ486K is the active metal coordination site. In addition, further evidences of Mg(II) complexation by BJ486K are obtained by comparing the IR bands related to the C=O stretching. For the first C=O band lying at 1675 cm-1 for the free flavone, a Δν(CO) of about 22 cm-1 is measured upon Mg(II) complexation while for the second band centered at 1608 cm-1, a Δν(CO) of about 16 cm-1 is determined. These effects on the C=O stretching bands correlates perfectly with a complexed flavone. More importnantly, no free stearic acid is present in the sample. Stearic acid has a characteristic v(CO) band at about 1700 cm-1, which does not appear in the IR spectrum of the complexed flavone. By contrast, the IR signature of the complexed stearate are still present for the Mg(II)-BJ486K complex clearly indicating that these long chain alkyl-carboxylate auxiliary binders are involved in the Mg(II) coordination. -
Figure 23 : Antiviral activity of XM148: Huh-7.5 cells were incubated for 48h with renilla repoter virus (Jc1R-2a) in the presence of increasing concentrations of XM148 or BJ486K respectively. HCV infection was determined 48h post inoculation using luciferase assays and is expressed as % of cells treated with solvent alone. Results from a single experiment are shown. - The present invention is now further illustrated by the following examples, which are not construed to limit the broad aspects of the invention disclosed herein.
- The synthesis of flavone 13 and of its
fluorine analogues 14, 15 was executed in a straightforward manner as outlined inReaction Scheme 1. The commercially available 4,6-dimethoxy-2-hydroxy acetophenone was subjected to Elbs oxidation (Elbs, 1893) using sodium persulfate and aqueous sodium hydroxide to afford the substitutedacetophenone 1 in yield between 31 - 64 %. The reaction conditions were applied according to reported procedure but with slight modifications. The yield of the first step is significantly increased upon addition of solid potassium persulfate to the 2-days-old reaction mixture and upon several acidic treatments and heating of the reaction mixture. The generation of thetrilithium trianion 2 of theacetophenone 1 was produced by treatment with LiHMDS (Lithium hexamethyldisilylazide). Treatment of trilithium trianion 2 with commercially available benzoyl chloride (3, 4, 5), followed by acidification, afforded the diketone intermediates (6, 7, 8), which were used without further purification for cyclization. Thecrude intermediates flavone 10. Thus, a short and economical synthesis of theflavone 10 was performed in 56% overall yield following a 4 steps-sequence from theacetophenone 1. In the case of fluorine analogues the cyclization and the cleavage of the ester group was observed in one step. Final demethylation offlavone 10 was achieved in the presence of boron tribromide affording the flavone 13 (herein also referred to as flavone 13, compound 13 or BJ486K; notably, BJ486K is the synthetic counterpart of the structurally identical flavonoid MP03 (also known as ladanein) isolated from plant extracts of Marrubium peregrinum Lamiaceae) after hydrolysis by methanol in high 82% yield as well as the demethylation step offlavones 11, 12 to afford 14 and 15 in 93% yield and 27% yield, respectively. Purification of final very pure flavones was performed by low pressure column chromatographic techniques (Sephadex LH20 and CH2Cl2/CH3OH gradients) under nitrogen, and the structures elucidated by NMR and ESI-MS. - A mixture of water (20 mL), dibromomethane(150 mmole) and Adogen 464 (1 mnole) was rigorously stirred and heated to reflux. The air in the system was displaced by Argon. A solution of the appropriate catecholflavones 13-15 (100 mmole) and sodium hydroxide (250 mmole) in water (50 mL) was added at such a rate that the addition was complete after 2 hours. After the addition was complete, the reaction mixture was stirred and refluxed for a further hour. The product 16-18 were then isolated by column chromatographic techniques and identified by NMR and ESI-MS.
- An improved synthesis of flavones 13-15 was designed in order to obtain the flavone BJ486K in large quantities with a quick and cheap pathway. The final synthesis is depicted in
Reaction Scheme 2. Final protection of the β-hydroxy ketone motif of BJ486K was performed by direct complexation with Mg complexes. - The synthesis starts with a reductive acetylation of the 2,6-dimethoxy-1,4-benzoquinone (1) in the presence of Zn to yield the
diacetate 2 with a quantitative yield.Product 2 undergoes a Fries rearrangement with boron trifluoride etherate in toluene to form the initial precursor of theflavone 3 with 70 % yield after a recrystallization. Both these reactions have been performed with more than 10 g of starting material. Next, the initial precursor is deprotonated in the presence of LiHMDS and undergoes a Baker-Venkataraman reaction in the presence of benzoyl chloride. Without further purification, the heterocycle is formed by heating in acetic acid and sulfuric acid. The final precursor is formed by cleaving the ester bond using LiOH, yielding theflavone 6 with 61 % yield from theinitial precursor 3. No silica gel column chromatography is needed thanks to an acid-base work-up which simplifies the purification. Therefore, the desired product is obtained by a simple recrystallization. Finally, the target molecule BJ486K is synthesized with 80 % yield by means of a selective demethylation using magnesium bromide in acetonitrile. To protect the flavone from oxidation, a magnesium complex was designed and prepared in the final step g). - To form the complex, 1 equivalent of BJ486K is dissolved in 1,4-Dioxane to give a yellow solution. Then 0.95 equivalents of magnesium stearate are added. The mixture is refluxed for 1 h. The final solution is orange, which is probably due to the formation of the complex. This observation correlates with the results obtained from the UV-Vis physico-chemical study (apparition of a low intensity band in the visible region). IR spectrum confirms the formation of the complex. The band corresponding to one of the hydroxy groups (3518 cm-1) is no longer present, the bands corresponding to the aromatic rings of the flavone shift slightly and a characteristic band of stearic acid (around 1700 cm-1) is not observed either in the IR spectrum of the complex.
Scheme 2. a) Ac2O, Zn, HCl, 5 min. 0 °C, quant. b) BF3·Et2O, PhMe, 110 °C, 18 h, 70 %. c) LiHMDS, THF, -78 °C to RT, 22 h. d) H2SO4, AcOH, 100 °C, 3.5 h. e) LiOH, THF, MeOH, 2 h., 61 % from c). f) MgBr2, MeCN, 80 °C, 3 h., 80 %. g) MgR2. - 4-(acetyloxy)-3,5-dimethoxyphenyl acetate (2). A cold (0 °C) solution of concentrated HCl (9 mL, excess) and Ac2O (50 mL, excess) was added to a mixture of 2,6-dimethoxy-1,4-benzoquinone (2.00 g, 11.89 mmol, 1 equiv) and Zn powder (5.83 g, 89.21 mmol, 7.5 equiv.). The mixture was stirred at 0 °C for 5 min. Et2O (75 mL) was added and the solid was filtrated. The organic phase was washed with water and brine, dried over magnesium sulfate and concentrated under reduced pressure, adding toluene to coevaporate the acetic acid, to yield a white solid (2.98 g, 11.73 mmol, quantitative yield). No further purification is needed. mp 126 °C; 1H NMR (CDCl3; 300 MHz): δ 6.40 (s, 2 H), 3.81 (s, 6 H), 2.34 (s, 3 H), 2.31 (s, 3 H); 13C NMR (CDCl3; 75 MHz): δ 169.4, 168.8, 152.6, 149.1, 126.6, 99.1, 56.4, 21.3, 20.6; IR (neat): 1754, 1615, 1504, 1423, 1179, 1129, 1018, 983, 909, 831, 567 cm-1.
- 1-(3,6-dihydroxy-2,4-dimethoxyphenyl)ethan-1-one (3). BF3·Et2O (0.3 mL, 2.36 mmol, 3 equiv.) was added dropwise to a solution of 4-(acetyloxy)-3,5-dimethoxyphenyl acetate (200 mg, 0.79 mmol, 1 equiv.) in toluene (8 mL) and the mixture was heated to 110 °C for 18 h. Then, water (10 mL) and a saturated solution of NH4Cl (10 mL) are added and the aqueous phase is extracted three times with ethyl acetate. The separated organic layer was washed with water and brine, dried over magnesium sulfate and concentrated under reduced pressure to yield a brown solid. The solid was diluted in CH2Cl2, filtered through silica gel, evaporated and recrystallized from CH2Cl2/CHex to yield a bright yellow solid (120 mg, 0.55 mmol, 70 % yield). mp 162 °C; 1H NMR (CDCl3; 300 MHz): δ 13.20 (s, 1 H), 6.28 (s, 1 H), 5.15 (br. s, 1 H), 3.97 (s, 3 H), 3.94 (s, 3 H), 2.69 (s, 3 H); 13C NMR (CDCl3; 75 MHz): δ 203.4, 158.9, 154.0, 147.4, 131.2, 108.5, 95.5, 60.7, 56.3, 31.6; IR (neat): 3261, 1630, 1594, 1499, 1433, 1078, 1230, 959, 892, 820, 593 cm-1; FAB+ MS: 213.2 [M+H]+.
- 6-Hydroxy-5,7-dimethoxy-2-(4-methoxy-phenyl)-chromen-4-one (6). A solution of LiHMDS was prepared by adding 20.6 mL of n-BuLi (1.6 M in hexanes, 32.96 mmol, 7 equiv.) to a solution of freshly distilled HMDS (7.2 mL, 34.35 mmol, 7.3 equiv.) in dry THF (20 mL) at 0 °C. The mixture was stirred at that temperature for 30 min and then was added dropwise to a solution of 1-(3,6-dihydroxy-2,4-dimethoxyphenyl)ethan-1-one (1.00 g, 4.71 mmol, 1 equiv.) in dry THF (60 mL) under Ar atmosphere and at -78 °C. The mixture was left to stir for 1 h at that temperature, 2 h at -10 °C and then it was cooled down to -78 °C again. A solution of 4-methoxybenzoyl chloride (1.30 mL, 9.65 mmol, 2.05 equiv.) in dry THF (20 mL) was added and the reaction was stirred for 1 h at that temperature and at room temperature overnight. The solution was poured into a mixture of crushed ice and concentrated HCl, extracted three times with CH2Cl2, dried over magnesium sulfate and concentrated under reduced pressure to yield a brown solid. The solid was then dissolved in acetic acid (40 mL), H2SO4 (0.5 mL) was added and the reaction was heated at 95 °C for 3.5 h. Then, the solvent was evaporated under reduced pressure, water was added and the aqueous phase was extracted three times with CH2Cl2. The organic phase was dried over magnesium sulfate and the solvent was evaporated under reduced pressure to yield a dark brown solid. The solid was then dissolved in THF (50 mL), and a solution of LiOH (700 mg, 29.23 mmol, excess) in MeOH (15 mL) was added. The reaction was stirred at room temperature for 2 h. The solution was poured into water and acetic acid was added until
pH 5. The aqueous phase was extracted three times with CH2Cl2, then the organic phase was thoroughly washed with a 0.5 M solution of NaOH. The aqueous phase was then acidified to neutral pH with a 1 M solution of HCl and the aqueous phase was extracted three times with CH2Cl2. After concentration under reduced pressure and a recrystallization from water/EtOAc, a light brown solid was obtained (0.94 g, 2.86 mmol, 61 % yield). mp 222-223 °C, 1H NMR (CDCl3; 300 MHz): δ 7.84 d, J=8.9 Hz, 2 H), 7.02 (d, J=8.9 Hz, 2 H), 6.84 (s, 1 H), 6.61 (s, 1 H), 5.93 (s, 1 H), 4.04 (s, 3 H), 4.03 (s, 3 H), 3.90 (s, 3 H); 13C NMR (CDCl3; 75 MHz): δ 177.0, 162.1, 161.4, 152.1, 151.9, 144.0, 136.6, 127.6, 124.0, 114.4, 112.3, 106.9, 96.2, 62.6, 56.4, 55.5; IR (neat): 3281, 1602, 1498, 1358, 1249, 1182, 1111, 838, 827, 555 cm-1; FAB+ MS: 329.10 [M+H]+. - 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one (BJ486K). To a solution of 6-Hydroxy-5,7-dimethoxy-2-(4-methoxy-phenyl)-chromen-4-one (152.7 mg, 0.46 mmol, 1 equiv.) in acetonitrile (10 mL) was added MgCl2 (172.6 mg, 0.92 mmol, 2 equiv.). The reaction mixture was stirred for 3 h. Then a solution of HCl 0.5 M was added and the aqueous phase was extracted with ethyl acetate. The organic phase was washed three times with HCl 0.5 M, water and brine. The separated organic layer was dried over magnesium sulfate and concentrated under reduced pressure to yield a bright yellow solid (116.3 mg, 0.37 mmol, 80 % yield). mp 215 °C dec.; 1H NMR (DMSO-d6; 300 MHz): δ 12.62 (s, 1 H), 8.73 (s, 1 H), 8.07 (d, J= 8.8 Hz, 2 H), 7.13 (d, J=8.8 Hz, 2 H), 6.96 (s, 1 H), 6.91 (s, 1 H), 3.94 (s, 3 H), 3.88 (s, 3 H); 13C NMR (DMSO-d6; 75 MHz): δ 182.2, 163.3, 162.2, 154.4, 149.6, 146.2, 129.9, 128.2, 123.0, 114.5, 105.1, 103.1, 91.2, 56.3, 55.5; IR (neat): 3518, 1482, 1464, 1359, 1248, 1179, 1108, 1035, 830, 803, 558 cm-1; HRMS (ESI+) : 315.09 [M+H]+.
- Magnesium stearate complex of XM148 (XM150). Magnesium stearate (54.8 mg, 0.093 mmol, 0.94 equiv.) was added to a solution of 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one (30.9 mg, 0.10 mmol, 1 equiv.) in dioxane (8 mL) at 100 °C. The mixture was heated for one hour and the colour changed from yellow to orange. The solvent was evaporated under reduced pressure and the solid recrystallized in acetonitrile to yield an orange solid. IR (neat): 2917, 2849, 1577, 1456, 1304, 1259, 1178, 1133, 833. Compared 1H NMR data of the free flavone and of the magnesium stearate complex in CDCl3: 1H NMR (300 MHz, CDCl3) 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one: δ 12.59 (s, 1H), 7.84 (d, J = 8.9 Hz, 2H), 7.02 (d, J = 8.9 Hz, 2H), 6.59 (s, 2H), 4.00 (s, 3H), 3.89 (s, 3H); 1H NMR (300 MHz, CDCl3) Magnesium stearate complex: δ 7.86 (m), 7.02 (m), 6.56 (m), 4.19 (s), 3.88 (s, 3H), 2.30 (s, 2H), 1.60 (s, 2H), 1.27 (s, 56 H), 0.89 (s, 3H). When both spectra are compared, there is the disparition of the peak corresponding to the hydroxy group in β-position to the carbonyl group. Peaks corresponding to aromatic protons of the flavone have slightly shifted. Peaks corresponding to the stearate appear also slightly shifted (2.30 ppm instead of 2.35 for stearic acid, 1.60 instead of 1.64, 1.27 instead of 1.26 and 0.89 instead of 0.88). Finally, it is interesting to notice that no stearic acid is present since the characteristic peak of the carboxylic group around 11 ppm is not present.
- Magnesium chloride complex of XM148 (XM156). MgCl2 (163.3 mg, 0.8 mmol, 5 equiv.) was added to a solution of 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one (50.5 mg, 0.16 mmol, 1 equiv.) in acetonitrile. The mixture was stirred at 80 °C during an hour. The colour of the mixture changed from yellow to orange. The solvent was evaporated under reduced pressure to yield an orange solid. Compared 1H NMR data of the free flavone and of the magnesium chloride complex in DMF-d7: 1H NMR (300 MHz, DMF-d7) 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one: δ 12.71 (s, 1H), 8.10 (d, J = 8.9 Hz, 2H), 7.17 (d, J = 8.9 Hz, 2H), 7.00 (s, 1H), 6.84 (s, 1H), 4.00 (s, 3H), 3.93 (s, 3H); 1H NMR (300 MHz, DMF-d7) Magnesium chloride complex: δ 8.04 (m, 2H), 7.08 (d, J=8.9 Hz, 2H), 6.97 (s, 1H),6.76 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H). Once again, when the complex is formed, the peak corresponding to the hydroxy group in β-position to the carbonyl group disappears. Also, all other peaks slightly shift due to the complexation.
- Huh7-Lunet/CD81 cells, a derivative of Huh-7 cells highly permissive for HCV RNA replication and infection (Koutsoudakis et al., J.Virol. 2007;81:588-598), were cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) with 10% fetal bovine serum (FCS Gold, PAA, Coelbe, Germany), 1x non-essential amino acids (Invitrogen), 100 µg/ml streptomycin (Invitrogen) and 100 IU/ml penicillin (Invitrogen), 2 mM L-glutamine (Invitrogen) and 750 µg/ml geneticin (Carl Roth, Germany).
- In vitro transcripts were generated and transfected using electroporation as described recently (Koutsoudakis et al., J.Virol. 2006;80:5308-5320).
- Huh7-Lunet/CD81 cells were infected with reporter virus particles essentially as described recently (Koutsoudakis et al., J.Virol. 2006; 80: 5308-5320). Briefly, for inoculation with firefly luciferase reporter virus particles (Luc-Jc1) and Renilla reporter viruses (JcR-2a (Reiss et al., Cell host & microbe 2011; 9: 32-45) and GT1-6, see plasmids below), Huh7-Lunet/CD81 cells were seeded at a density of 6×10e4 cells per well of a 12-well plate or 6.6×10e3 cells per well of a 96-well plate 24h prior to inoculation. If not stated otherwise, the virus particles were pretreated with the inhibitors for 1h at 37°C. Cells were inoculated for 4h at 37°C, viral inoculum was replaced by fresh culture fluid and infection was quantified 48h or 72h after virus inoculation using luciferase assays. To this end, cells were washed once with PBS and in the case of the Luc-Jc1 infected cells, lysed directly on the plate with 350 µl of cold lysis buffer (0.1% Triton-X100, 25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA and 1 mM dithiothreitol, pH 7.8) and after addition of the luciferase solution (200 µM luciferin, 25 mM glycylglycine, pH8) measured for 20s in a luminometer (Lumat LB9507, Berthold, Freiburg, Germany). Cells infected with the renilla reporter virus were lysed in 200 µl lysis buffer (Promega, Mannheim, Germany) and after addition of the luciferase substrate (1 µM of coelenterazin (P.J.K., Kleinblittersdorf, Germany) in PBS) measured for Is in a luminometer (Lumat LB9507, Berthold, Freiburg, Germany). The indicated IC50 values were determined by using Sigma Plot software (Systat Inc; San Jose; CA).
- The plasmids pFK-Luc-Jc1 and pFK-Jc1 encoding the
intragenotypic 2a/2a chimeric virus Jc1 with or without firefly luciferase reporter gene as well as the plasmid pFKi389RLuc2aCore-3'-Jc1 (5 referred to as JcR-2a) have been described. Briefly, JcR-2a is a monocistronic reporter virus derived from the Jc1 chimera that expresses a Renilla luciferase (RLuc) that is fused N-terminally with the 16 N-terminal residues of the core protein. C-terminally RLuc is connected to the Jc1 open reading frame through the foot-and-mouth disease virus (FMDV) 2A peptide coding region which liberates the reporter from the downstream HCV proteins. This construct was used to create infectious monocistronic RLuc reporter virus genomes for all six major genotypes. Briefly, chimeric HCV open reading frames encoding core, E1, E2, p7 and NS2 of the GT1a isolate H77C, the GT1b isolate J4, the GT2b isolate J8, the GT3a isolate S52, the GT4a isolate ED43, the GT5a isolate SA13, or the GT6a isolate HK6a, respectively, followed by JFH1-derived NS3 to NS5B genes were cloned downstream of the R2a-reportergene cassette. The resulting novel monocistronic Renilla luciferase reportervirus genomes were designated H77c/1a/R2a, J4/1b/R2a, J8/2b/R2a, S52/3a/R2a, ED43/4a/R2a, SA13/5a/R2a, HK6a/6a/R2a. - Env-deleted HIV-1-GFP reporter viruses, which had been pseudotyped with the R5 envelope from YU-2, were incubated with various concentrations of BJ486K or its naturally occurring counterpart MP03 extracted and isolated from plant extracts of Marrubium peregrinum Lamiaceae. Briefly, TZM-bl cells were challenged with these viruses overnight, washed and subsequently cultivated under standard conditions. Three days post-infection the percentage of infected, GFP-positive cells was quantified by flow cytometry. Values obtained for solvent-treated controls were set to 100%. Shown are arithmetic means ± SD (n=3) from one of three independent experiments. IC50 values were determined by using Prism software (GraphPad, San Diego, CA).
- Replication competent GFP-tagged vesicular stomatitis virus (VSV-GFP) was incubated with various concentrations of BJ486K for 1h at 37°C prior to infection of Vero-CH, A549 or Huh-7.5 cells, respectively. Virus titers were analysed using limiting dilution assays. In brief, cells were inoculated with serially diluted virus preparations with six replicate wells of a 96-well plate per dilution. Cells were fixed with 3
% paraformaldehyde 48h to 72h after infection and in the case of CoxV and AdV5 infection stained with coomassie solution (0.25% Coomassie brilliant blue R-250, 45% methanol, 10% acetic acid) to identify infected wells. In case of VSV infections, we used a recombinant vesicular stomatitis virus expressing enhanced green fluorescent protein designated VSV*MQ. This virus carries four attenuating mutations in the M protein, and expresses GFP from an additional transcriptional unit located between G and L. VSV*MQ infected cells were identified by detection of GFP-autofluorescence using a Olympus IX-81 microscope. Virus titers (50% tissue culture infective dose [TCID50/ml]) were calculated based on the method of Spearman and Kärber. - Huh7-Lunet/CD81 cells were transfected with Jc1 RNA and seeded on a 6-well plate. Compounds were added 4h later. At 48h after transfection, cell culture supernatant was harvested and used for measuring the extracellular core amount. Cells were washed once with PBS, scraped and centrifuged for 5 min at 1000×g. Cell pellets were resuspended in 500 µl fresh culture fluid and subjected to three cycles of freeze and thaw using liquid nitrogen and a 37°C thermo block. Samples were than centrifuged at 10,000xg for 10 min to remove cell debris and the core amount was measured (intracellular core protein) using the ARCHITECT HCV Core AG test (Abbott, Wiesbaden, Germany) according to the instructions of the manufacturer.
- Cytotoxicity was measured using the CytoTox-Glo cytotoxicity assay (Promega, Mannheim, Germany) as described by the manufacturer employing a plate luminometer Centro XS LB960 (Berthold, Freiburg, Germany) according to the manufacturer's instructions.
- JcR-2a virus particles were incubated with Huh7-Lunet/CD81 cells seeded as described above for 1h at 4°C to synchronize cell entry. Various inhibitors including 50 µg/ml heparin (Sigma-Aldrich), CD81-specific antibody JS-81 (2 µg/ml; Becton Dickinson), ITX 5061 (10 µM) or BJ486K (20 µM), were added during virus inoculation (protocol 1) or at indicated time points after virus inoculation (protocol 2-8). After 4h inhibitor treatment, medium was changed to fresh culture fluid without inhibitors and the cells were lysed 48h after inoculation as described above. Efficiency of infection was determined by luciferase assay using a tube luminometer (Lumat LB9507, Berthold, Freiburg, Germany).
- Virus titers were measured using the limiting dilution assay as described recently (Steinmann et al., J.Virol. 2008; 82: 7034-7046). Virus titers (50% tissue culture infective dose [TCID50/ml]) were calculated based on the method of Spearman and Kärber (Spearman C., British Journal of Psychology 1908; 2: 227-242; Kärber G., Archiv für experimentelle Pathologie und Pharmakologie 1931; 162: 480-487).
- Normal-appearing liver tissue from patients seronegative for HCV, hepatitis B virus, and human immunodeficiency virus (HIV) was obtained from adult patients undergoing partial hepatectomy for the therapy of metastases. Experimental procedures were carried out in accordance with French Laws and Regulations. Hepatocytes were isolated by a two-step perfusion technique and maintained in primary culture as described previously (Podevin et al., Gastroenterology 2010; 139: 1355-64). Cells were inoculated with Con1/C3-HCV (Pietschmann et al., Proc. Natl. Acad. Sci. U.S.A 2006; 103: 7408-7413) grown in Huh-7.5.1 cells at a multiplicity of infection of 0.1 in the presence of dimethylsulfoxide as carrier control, or else increasing concentrations of BJ486K. Three days later, infectivity titers in culture supernatants were determined by focus-formation assay as previously described by (Pene et al., Journal of Viral Hepatitis 2009;16:705-15).
- To characterize the antiviral effect of BJ486K, the impact of BJ486K on the steps of HCV RNA translation and replication was assessed. To this end, Huh7-Lunet/CD81 cells were transfected with a subgenomic JFH1 luciferase replicon and RNA replication was monitored 72h later by luciferase assays. As control we incubated the cells with increasing doses of the NS3-4A protease inhibitor boceprevir and the polymerase inhibitor 2'-C-methyladenosine (2'CMA). As shown in
Figure 2A , BJ486K affected neither RNA translation nor replication of HCV RNA as luciferase activity was not changed up to a dose of 10µM. - To determine whether BJ486K affects virus assembly or release we transfected Huh7-Lunet/CD81 cells with Jc1 RNA and quantified intra- and extracellular levels of
core protein 48h after transfection (Figure 2B ). As expected, both quinidine and the grapefruit flavonoid naringenin, two assembly inhibitors recently identified using the JFH1-based infection system, selectively reduced extracellular levels of core protein by more than 100- or ca. 5-fold, respectively, thus confirming their interference with HCV virus production. In contrast, BJ486K reduced neither intracellular nor extracellular core protein levels up to a dose of 20 µM, which is 10-fold higher than the determined IC50 value (Figure 1 ). Collectively these data indicate that different flavonoids can prevent HCV propagation by distinct mechanisms and that BJ486K does not impede HCV RNA translation, RNA replication and virus production. In agreement with this conclusion, addition of BJ486K only interfered with HCV infection when the drug was present during virus inoculation, whereas addition of the compound before or after virus inoculation did not preclude productive cell entry and subsequent RNA replication (Figure 2C ). - To resolve which step of HCV cell entry is inhibited by BJ486K, we assessed its antiviral activity when administered at different time points during the early phase of infection. To this end, Huh7-Lunet/CD81 cells were inoculated for one hour at 4°C with a reporter virus prepared in the absence of drugs. At this temperature, virus particles bind to the cell surface but do not efficiently enter, thus permitting a rather synchronous infection when the inoculum is removed and cells are shifted to 37°C. A selection of HCV entry inhibitors which prevent infection by different mechanisms or BJ486K were added during inoculation, directly afterwards or at different intervals shortly thereafter. To attain maximal sensitivity we used a novel monocistronic renilla luciferase reporter virus based on the
intragenotypic genotype 2a chimera Jc1 which is designated JcR-2a and that was described recently (Reiss et al., Cell host & microbe 2011; 9: 32-45) (Figure 3 ). As expected, heparin which is known to impede HCV cell attachment only interfered with HCV infection when present already during inoculation (Figure 3 ). In contrast, BJ486K like CD81-specific antibodies, potently inhibited entry not only when present during inoculation but also when added directly after virus binding (>90% inhibition). In fact, administration of thedrug 20 minutes post virus attachment still inhibited ca. 80% of HCV infection, clearly indicating that BJ486K blocks a post-binding step of the HCV entry pathway. The kinetics of BJ486K-mediated blockade of HCV cell entry were comparable to CD81-specific antibodies and also to ITX5061, a clinical stage compound that is thought to interfere with HCV infection through inhibiting viral interaction with SR-BI. - BJ486K is not affected by viral resistance against a SR-BI-targeting entry inhibitor, inhibits HCV of all major genotypes and impedes infection of primary human hepatocytes. Syder et al. recently reported that a specific mutation within the HCV envelope protein E2 (G451R) that is known to reduce viral dependency on SR-BI for cell entry (J.Hepatol. 2011; 54: 48-55) at the same time reduces the susceptibility of HCV towards inhibition by ITX506128. These data indicate that decrease of SR-BI receptor dependence by HCV is a possible viral escape mechanism from inhibition by SR-BI-targeting antivirals. Therefore, to explore whether this viral resistance mechanism also compromises the antiviral activity of BJ486K we compared the antiviral activity of the two compounds against wild type and the mutant virus carrying the G451R exchange within E2. In line with the report by Syder et al., the aforementioned mutation rendered HCV resistant to inhibition by ITX5061 (
Figure 4A ). In contrast, the antiviral activity of BJ486K was not changed by this mutation (Figure 4B ), indicating that reduced SR-BI dependence does not confer resistance towards entry inhibition by BJ486K. - Efficacy of current HCV treatment is substantially influenced by viral genotype. More specifically, IFN-based therapy regimens attain sustained viral response rates of ca. 80% in patients infected with
genotype genotype 1 reach only about 50%30. Moreover, directly targeted antivirals in late stage clinical development vary in efficacy depending on the viral genotype. Therefore, we determined the antiviral activity of BJ486K towards HCV particles from different genotypes. To be able to resolve different response rates among these viruses with highest resolution, we created a set of novel reporter virus constructs based on the JcR-2a backbone (Figure 3 ). Importantly, antiviral activity of BJ486K against cell culture derived particles fromgenotype Figure 4C and Table 1).Table 1. Antiviral activity of BJ486K across all major HCV genotypes HCV Isolate IC50 [µM] IC90 [µM] H77c (GT1a) 2,46 11,64 J4 (GT1b) 2,35 9,29 J8 (GT2b) 4,14 8,42 S52 (GT3a) 2,89 10,65 ED43 (GT4a) 0,74 1,78 SA13 (GT5a) 1,39 5,33 HK6a (GT6a) 0,75 2,39 - Although human hepatocellular carcinoma derived cell lines sustain the entire HCV replication cycle and are a well-accepted model for HCV infection studies, these cells nevertheless functionally differ from primary human hepatocytes. Therefore, to confirm the antiviral activity of BJ486K in a more natural system, primary human hepatocytes were inoculated in the presence or absence of BJ486K with a cell culture derived
genotype 1b virus (Con1/C3; 24). As shown inFigure 4D , Con1/C3 infection of primary human hepatocytes was inhibited by BJ486K in a dose-dependent fashion with an IC50 value of ca. 10µM. - Bioavailability of BJ486K. Mice (24 in total) were treated either orally or intraveniously with a single dose of 0.25 mg/kg of the inhibitor (solved in saline/10% cremophor EL). At different time points after inhibitor administration (5 min, 15 min, 30 min, 60 min, 120 min or 180 min) two mice from each group were sacrified and the blood was centrifuged to obtain the plasma, which was stored at -80°C until further examination. 400 µl of each plasma sample was mixed with equal amount of a 2% trifluoroacetic acid and loaded on a SPE Strata C18 column (equilibrated with 1 ml methanol and 1
ml 1% trifluoroacetic acid) for solid phase extraction of the plasma. After several washing steps (1% trifluoroacetic acid and water), the samples were eluted with acetonitrile and dried. The remaining sample was resolved in 25 µl acetonitrile:water (ratio 1:1). Samples were further analyzed with a LC-MS/MS (triple quadrupole mass spectrometer LCMS 8030 Shimadzu), which was calibrated at the day of measurement. Plasma drug concentrations versus time curves were plotted for each route. Bioavailability was calculated by dividing the area under curve (AUC) for oral route by the AUC for intravenous route. The results are shown inFigure 10 . - BJ486K exerts synergistic antiviral activity with Cyclosporine A (CsA) and prevents productive infection of differentiated human hepatoma cells. Next, we investigated if combination of CsA, an inhibitor of HCV RNA-replication in vitro and in vivo and also an immunosuppressive drug used in the HCV post-transplant setting, with BJ486K would increase antiviral potency. To this end, we challenged Huh7-Lunet/CD81 cells differentiated by DMSO-treatment with the highly infectious Jc1 chimera in the presence of CsA, BJ486K or a combination of both drugs (
Figure 5 ). In this quiescent, growth arrested cell culture we monitored virus production for 12 days after inoculation to find out if drug treatment had completely eliminated virus infection. The applied dose of CsA was not sufficient to prevent infection of the cells and resulted in only about 5 to10-fold lower levels ofinfectious virus 12 days after inoculation (Figure 5B ). In contrast, BJ486K reduced infection almost down to background levels (Figure 5C ). Remarkably, combination of both drugs completely eliminated infection as is evident from absence of detectable infectious virus atdays Figure 5D ). To obtain a more quantitative measure for the combined antiviral effect of BJ486K and CsA, we inoculated naive Huh7-Lunet/CD81 cells with JcR-2a virus together with varying doses of both drugs (Figure 6A ). Importantly, addition of 1µM of BJ486K decreased the IC50 of CsA by more than 10-fold (left panel) and vice versa, as little as 100 ng/mL of CsA decreased the IC50 of BJ486K by ca. 3-fold to ca. 400 nM. Therefore, based on the combination index calculation described by Zhao et al.(Clin Cancer Res 2004; 10: 7994-8004) BJ486K and CsA synergistically inhibited HCV infection (Figure 6B ; Table 2). Of note, first pharmacokinetic data of BJ486K administered to mice indicate bioavailability of the drug and peak plasma levels of 329 nM after a single oral dose of 0.25 mg/kg (Figure 10 ). Collectively, these results indicate that combination of these inhibitors dramatically increases antiviral potency which is sufficient to prevent infection of cultured cells with a high dose of infectious HCV.Table 2. Combined effect of BJ486K and CsA inhibitors IC90 CI BJ486K 4,37 µM CsA >1000 ng/ml BJ486K + 100 ng/ ml CsA 3,03 µM 0,793 BJ486K + 200 ng/ ml CsA 2,8 µM 0,840 BJ486K + 300 ng/ ml CsA 2,5 µM 0,872 - As new drug combination with BJ486K, the antimalarial chloroquine (CQ) known as an HCV entry inhibitor (Ashfaq, U.A. et al., Virol J. 2011, 8:163) was tested in drug combination with the flavone BJ486K and analogs, in conditions similar to the one performed with BJ486K + CsA. Chloroquine alone has a dose-dependent anti-HCV effect (with no cytotoxicity detectable at the used concentrations,
Fig 11 A ). An additive effect (depicted in % change over expected value (no mountain, no valley) was observed with the flavone BJ486K and the known lysosomotropic agent CQ (Figure 11 B) . This effect was seen in all repeat experiments with no significant difference. - The physico-chemical properties of BJK486K and its ferric complexes were examined in a mixture methanol/water (80/20 by weight). Distilled water was further purified by passing through a mixed bed of ion-exchanger (Bioblock Scientific R3-83002, M3-83006) and activated carbon (Bioblock Scientific ORC-83005). Both, distilled water and spectroscopic grade methanol (Merck, Uvasol®, p.a.) were deoxygenated using CO2- and O2-free argon prior to use (Sigma Oxiclear cartridge). All the stock solutions were prepared by weighing solid products using an AG 245 Mettler Toledo analytical balance (precision 0.01 mg). The complete dissolution of the ligands was obtained with the help of ultrasonic bath. The ionic strength was adjusted to 0.1 M with tetraethylammonium perchlorate (NEt4ClO4.H2O, Fluka, puriss.). Iron(III) perchlorate stock solutions (Fluka) were freshly prepared in water at acidic pH (pH < 1.5) immediately before use and their concentrations were ascertained by UV-visible absorption spectrophotometry (ε338= 2,115 x 104 M-1 cm-1 et ε268= 1,845 x 104 M-1 cm-1; R. Bastian, R. Weberling, F. Palilla, "Determination of Iron by Ultraviolet Spectrophotometry" Anal. Chem., 1956, 28, 459-462.). The glassware used was rinsed after each experiment with a hydrochloric acid solution to remove all traces of iron.
- The free hydrogen ion concentrations were measured with a combined glass electrode (Metrohm 6.0234.500, Long Life) filled with 0.1 M NaCl (Fluka, p.a.) in MeOH/H2O (80/20 by weight). Potential differences were given by an automatic titrator system DMS 716 Titrino (Metrohm). The combined glass electrode was calibrated as a hydrogen ion concentration probe by titrating known amounts of perchloric acid (∼ 10-1 M from HClO4, Fluka, ∼ 70% in water) with CO2-free tetraethylammonium hydroxide solution (∼ 10-1 M from Et4NOH, Merck, ∼ 40% in water) in MeOH/H2O solvent (80/20 by weight). The HClO4 and NEt4OH solutions were freshly prepared just before use and titrated with sodium tetraborate decahydrate (B4Na2O7.10H2O, Fluka, puriss, p.a.) and potassium hydrogen phthalate (C8H5KO3, Fluka, puriss, p.a.), respectively, using methyl orange and with phenolphthalein (Prolabo, purum) as the indicators. The titration cell was thermostated at 25.0(2) °C by the flow of a Lauda E200 thermostat. A stream of argon, pre-saturated with water vapor, was passed over the surface of the solution. The Glee program (P. Gans, B. O'Sullivan "GLEE, a new computer program for glass electrode calibration" ) was applied for the glass electrode calibration (determination of the standard electrode potential E0/mV and of the slope of the electrode/mV.pH-1) and to check carbonate levels of the NaOH solutions used (< 5% within all the solutions tested).
- For the characterization of the BJ486K:Fe(III) complexes (method of continuous variations), stock solutions of BJ486K and iron(III) were freshly prepared under acidic conditions ([HClO4]tot = 10-2 M; pH ∼ 2.0) and were diluted to obtain the same concentration for both solutions at 4.94 × 10-5 M. The ionic strength was kept constant at 0.1 M with tetraethylammonium perchlorate (Et4NClO4, Fluka, puriss.). UV-Vis absorption spectra of mixtures with different [BJ486K]tot/([BJ486K]tot +[Fe(III)]tot) ratios were measured in a 1 cm Hellma optical cell with a Cary 300 (Varian) spectrophotometer. The Job's plot was processed with Origin program. The results are shown in
Figure 12 . The BJ486K:Fe(III) complex predominantly has a 1:1 stoichiometry with the metal binding site being the β-hydroxy-ketone unit as evidenced by a comparative study with salvigenin, a 6-methylated BJ486K derivative. - Stock solution of BJ486K was prepared in CH3OH/H2O (80/20 by weight) and then freshly diluted with HClO4 (10-2 M) to obtain a ligand concentration of ∼ 5.92 × 10-5 M. The ionic strength was kept constant at 0.1 M with tetraethylammonium perchlorate (Et4NClO4, Fluka, puriss.). The spectrophotometric titrations of BJ486K by Fe(III) were thus carried out on solutions at pH ∼ 2 (10-2 M HClO4). Microvolumes of a concentrated solution of Fe(III) (2.4 × 10-4 M) were added to an aliquot of 0.5 mL of the ligand solution in a 1 cm path length optical Hellma cell (the [Fe(III)]tot/[BJ486K]tot ratio varied from 0 to 1.60). Special care was taken to ensure that complete equilibration was attained. The corresponding UV-Vis spectra were recorded from 230 nm to 800 nm on a Cary 300 (Varian) spectrophotometer maintained at 25.0(2) °C by the flow of a Lauda E200 thermostat. The results are shown in
Figure 13 and confirm that flavone BJ486K firmly binds Fe(III) through its β-hydroxy-ketone chelating unit. - Spectrophotometric titration of the Fe(III) complexes with flavone BJ486K as a function of pH was performed. Due to Fe(III)-catalyzed oxidation of BJ486K under neutral conditions, a specific protocol was adopted. A stock solution of BJ486K was freshly prepared by quantitative dissolution of a solid sample in CH3OH/H2O (80/20 by weight), which was further diluted to get a ligand concentration of 4.55 × 10-5 M. The ionic strength was adjusted to 0.1 M with NEt4ClO4 (Fluka, puriss). For each pH measurement, an aliquot of 2 mL of the solution was introduced into a 1 cm Hellma quartz optical cell and 37.0 µL of the Fe(III) stock solution (2.24 × 10-3 M) was added. After each addition of base (Et4NOH) or acid (HClO4), the solution was mixed and its corresponding pH value was measured using a combined glass electrode (Metrohm 6.0234.500, Long Life) and an automatic titrator system 716 DMS (Metrohm). Special care was taken to ensure that complexation equilibration was attained. The absorption spectra vs. pH (1.72 < pH< 6.79) were thus recorded using a Cary 300 (Varian) spectrophotometer. The results are shown in
Figure 13 . Three protonated species of the monoferric monochelates with the flavone BJ486K exist. - With respect to the biological tests of the antiviral activity of BJ486K performed at pH 7.5-8, it was of importance to find appropriate conditions to study iron(III) complexation by BJ486K under comparable conditions. Exogenous chelators such as citrates or nitrilotriacetic acid (NTA) have been usually used to ensure iron solubility at pH 7.4 ((a) G. W. Bates, C. Billups, P. Saltman "The Kinetics and Mechanism of Iron(III) Exchange between Chelates and Transferrin. I. The Complexes of Citrate and Nitrilotriacetatic Acid" J. Biol. Chem. 1967, 242, 2810-2815. b) Y. Li, W. R. Harris, A. Maxwell, R. T. A. MacGillivray, T. Brown " Kinetic Studies on the Removal of Iron and Aluminum from Recombinant and Site-Directed Mutant N-Lobe Half Transferrins" Biochemistry 1998, 37, 14157-14166. c) J. M. El Hage Chahine, R. Pakdaman " Transferrin, a Mechanism for the Holoprotein Formation from Nitrilotriacetato-Fe(III)-Transferrin Mixed Complex" J. Chim. Phys. 1996, 93, 283-299. d) M. Gabricevic, D. S. Anderson, T. A. Mietzner, A. L. Crumbliss " Kinetics and Mechanism of Iron(III)-Nitrilotriacetate Complex Reactions with Phosphate and Acetohydroxamic Acid" Biochemistry 2004, 43, 5811-5819). We therefore used NTA in combination with BJ486K to characterize and quantify the corresponding ferric complexes. A stock solution of BJ486K (5.41 × 10-5 M) was freshly prepared in hepes aqueous buffer at pH 7.4 (0.1 M in CH3OH/H2O, 80/20 by weight) to obtain a ligand solution about. The ionic strength was adjusted to 0.1 M with tetraethylammonium perchlorate (Et4NClO4, Fluka, puriss.). The absorption spectrophotometric titration of BJ486K by FeNTA was carried out in a Hellma quartz optical cell (l = 1 cm). Microvolumes of a concentrated solution of FeNTA stock solution (2.41 × 10-3 M) were added to an aliquot of 2.0 mL of the ligand solution in a 1 cm path length optical Hellma cell (the [FeNTA]tot/[BJ486K]tot ratio varied from 0 to 2.0). After each addition the solution was mixed and special care was taken to ensure that complete equilibration was reached. The corresponding UV-Visible spectra were recorded on a Cary 300 (Varian) spectrophotometer. The results are shown in
Figure 15 . A ternary BJ486K:Fe(III):NTA complex is formed which is soluble under physiological conditions at pH 7.4. - The iron(III):BJ486K(:NTA) complex solutions were prepared as follows. Stock solutions were prepared and 200 µL of each solution was used:
- 1.) 400 µM BJ486K solution in 10% DMSO - 90% H2O
- 2.) 400 µM BJ486K : Iron :
ligand solution 10% DMSO - 90% H2O - 3.) 400 µM BJ486K :
Iron solution 10% DMSO - 90% H2O - 4.) 10% DMSO - 90% -H2O
- All final dilutions with medium DMEM high glucose were carried out immediately before addition of the solutions to the virus particles. Additionally, before use, the final solutions were checked for final concentration spectrophotometrically:
- 1.) 4 mM BJ486K solution in 100% DMSO
- 2.) Iron : ligand solution* in 100% H2O, pH 7.4
- 3.) Iron solution* in 100% H2O (freshly prepared on the day of testing)
- Specifically, the following stock solutions were prepared on the day of testing the compounds on their antiviral activity in a corresponding assay described above.
- 1.) 10% DMSO - 90 % H2O
- 2.) Preparation of 400 µM BJ486K/iron/ligand complex solutions in 10% DMSO - 90% H2O from stock solutions
- 3.) Dilution of 4.0 mM stock solution BJ486K in 100% DMSO to 400 µM solution in 10% DMSO - 90% H2O
- Final 1/10 dilution of 400 µM solutions in 10% DMSO - 90% H2O also employed virus particles and DMEM. The results are shown in
Figure 16 . BJ486K:Fe(III) complexes, in the presence and absence of NTA, inhibit HCV cell entry with the same potency as the uncomplexed BJ486K. - To prevent oxidation of the BJ486K flavone either in solution (i.e. we previously demonstrated - see above in the introduction - that base-catalyzed oxidation of the flavone may occur in aqueous solution) or in the solid state and to increase its bio-availability, we first envisaged to stabilize the flavone by metal complexation with a biological relevant redox-inert metal cation such as magnesium(II) or calcium(II), which are used in therapeutic formulations in human medicine. Mg(II) coordination properties with BJ486K (newly re-prepared as XM148) using MgCl2 was first examined. As the last step of the improved synthetic route to BJ486K involves deprotection of the 5-methoxyl group with the Lewis acid MgBr2, we anticipated that the deprotection/complexation steps may be performed in one pot, thus constituting a smart formulation approach. Because of the poor solubility of the magnesium salt in CH3CN (solvent used for the deprotection reaction), we used, for the physico-chemical approach, a mixed solvent made of 50% of CH3CN and 50 % of water to ensure solubilization of both reactants (XM148 and MgCl2).
Figure 17A depicted the spectral variations of the flavone-centered absorptions induced by Mg(II) chelation. Statistical analysis of the spectral data allowed us to calculate the stability constant of the XM148-MgCl2 complex (log K = 2.4 ± 0.3) as well as its electronic spectral properties (Figure 17B ). The flavone XM148 (= BJ486K) is characterized by two absorption maxima lying at 283 nm (band II) and 333 nm (Band I) assigned to the π-π* transitions of the B and A aromatic systems, respectively. Coordination of Mg(II) by the β-hydroxy-ketone bidentate site of BJ486K induced a bathochromic shift of the band II which apparently tends to blend with band I as well as formation of the new band in the visible region of much lower intensity. The spectroscopic signatures are unambiguous features of BJ486K (XM148) metal coordination processes. - As an additional evidence of Mg(II) complex formation through the β-hydroxy-ketone bidentate site of BJ486K, we conducted an absorption spectrophotometric titration of the final precursor B (= XM131 - the 5-OH is protected with a methyl group) by MgCl2 under comparable experimental conditions than those employed for BJ486K (
Figure 18 ). As anticipated, no Mg(II) complex is observed even under a large excess of Mg(II) thus further demonstrating that the β-hydroxy-ketone bidentate site of BJ486K is the metal chelation site. - The knowledge of the thermodynamic parameters of BJ486K/MgCl2 then allowed us to simulate the experimental conditions of a potential one-pot reaction (deprotection/complexation) of XM131 (the final precursor of BJ486K) with MgCl2 (
Figure 19 ). The relatively low stability of the BJ486K-MgCl2 complex indicated that a significant excess of MgCl2 is indeed required for formation of more than 95% of magnesium(II) complex (Figure 19 ) for [BJ486K] = 0.016 M (our standard experimental conditions for low scale preparation). Even though addition of excess of MgCl2 will undoubtedly accelerate the rate of the deprotection reaction (MgCl2 is indeed much less reactive than MgBr2), the final formulation will consequently contain high excess of MgCl2 and the low coordination stability might hamper flavone/MgCl2 accurate content determination. - To bypass these thermodynamic drawbacks, we then decided to discriminate the protection from the formulation (metal complex formation) steps. The final precursor XM131 was first reacted with MgBr2 to afford the pure BJ486K flavone (see improved synthetic route to BJ486K). BJ486K was then reacted in a last step with a biocompatible magnesium salt. Among the numerous magnesium(II) salts safely employed in pharmacological compositions (Mg(II) stearate, Mg(II) pidolate, Mg(II) lactate...), we first focused our attention on Mg(II) stearate as a proof of concept. Magnesium stearate melts at about 120 °C, is not soluble in water, and is generally considered safe for human consumption at levels below 2500 mg/kg per day. Magnesium stearate is also often used as an excipient in the manufacture of medical tablets, capsules and powders and might significantly decrease the release time of the active ingredients in tablets, which would significantly increase the rather low bio-availability of BJ486K (t1/2 ∼ 7 min in mice). To evaluate the stability of the Mg(II)-BJ486K complex when stearic acids are used as auxiliary ligands, we carried out an absorption spectrophotometric titration of BJ486K in pure dioxane. To circumvent the low solubility of Mg(II) stearate in dioxane, a concentrated stock solution was refluxed in this solvent and aliquots were added to a BJ486K solution in a quartz optical cell. Formation of the Mg(II) complex was monitor using absorption spectrophotometry.
Figure 20 displays the absorption spectrophotometric data. Even though the experimental conditions are different, the stability of the BJ486K-Mg(stearate)2 complex (log K = 4.1 ± 0.6) is two orders of magnitude higher with respect to that of BJ486K-MgCl2 (log K = 2.4 ± 0.3). This stabilization is clearly the result of the auxiliary stearate ligands and supports well our first hypotheses. The distribution diagrams provided inFigure 20 indicate that under the same conditions of reaction ([BJ486K] = 0.016 M), addition of only one equivalent would lead to the formation of more than 93% of the targeted complex, which can be purified and analyzed more conveniently. The experimental synthetic section describing the synthesis and characterization of the magnesium BJ486K complex under its stearate salt is given inFigures 20A and 20B . - Distribution diagrams calculated for the ternary Mg(stearate)2 : BJ486K complex allowed the evaluation of the amount of the magnesium(II) complex (93%) in solution (
Figure 21 ). - To protect the flavone from oxidative degradation, the preparation of a magnesium complex was investigated. To form the complex, 1 equivalent of BJ486K was dissolved in 1,4-dioxane to give a yellow solution. Then 0.95 equivalents of magnesium stearate are added. The mixture was refluxed for 1 h. The final solution became orange, likely because of the formation of the complex. This observation correlated well with the results obtained from the UV-Vis physico-chemical study (apparition of a low intensity band in the visible region). The obtained yellow-orange solid was found to be insoluble in most of the organic solvents commonly used. Efforts are now directed towards full characterization of the magnesium(II) stearate/BJ486K complex. First evidence that the Mg(II) stearate/flavone formulation is successful came from Infra Red spectroscopy measurements. IR spectra of the Mg(II) stearate, the flavone and the Mg(II) stearate/BJ486K complex were recorded and are provided in
Figure 22A .
It can be observed that the hydroxy stretching band appearing at 3157 cm-1 for the free flavone (5-OH) disappears completely once the flavone is complexed to the magnesium(II) (Figure 22B ). This is a clear proof that a chelation has taken place (Jose, C.I. et al., Spectrochimica Acta 1974, 30A, 1199) . Also, further proof of complexation can be stated by comparing the bands corresponding to the C=O stretching. Indeed, 5-hydroxy-flavonato complexes show v(CO) bands shifting towards a lower frequency by 14-35 cm-1, indicating that the 5-hydroxy-flavone is coordinated to the metal ion as a bidentate chelate (Figure 22C ) (Hiraki, K. et al., Bull. Chem. Soc. Jap. 1978, 51, 2425). Indeed, it can be observed that fromFigure 22C for the first C=O band lying at 1675 cm-1, there is a Δν(CO) of about 22 cm-1 and for the second band centered at 1608 cm-1, there is a Δν(CO) of about 16 cm-1, which correlates perfectly with a complexed flavone. Lastly, it is clear that no free stearic acid is present in the sample, because it has a very characteristic v(CO) band at about 1700 cm-1, which does not appear in the IR spectrum of the complexed flavone. By contrast, the IR signature of the complexed stearate are still present for the Mg(II)/BJ486K complex indicating that these long chain alkyl-carboxylate binders are still involved in the Mg(II) coordination. - CremophorEL (from BASF) in mixture with DMSO was used to solubilize the XM148-Mg-Stearate complex (XM150). The protocol for solubilizing is as followed:
Prepare 10 mM solution of XM150 in pure cremophorEL, then dilute to ½ with pure DMSO and let the sample at 60 °C in a rotative incubator (slow stirring) overnight. The day of the experiment, aqueous saline phosphate buffer (PBS) maintained at 60 °C was added, and the homogeneous solution was slowly diluted in a rotative incubator to final 1 mM of XM150 in aqueous PBS.
Claims (16)
- A compound of the general formula (I):
A is:Mb is a non electroactive metal ion under its divalent state selected from zinc, magnesium, calcium, copper, or M is trivalent iron; andR5 is a hydrogen atom or an acetyl group;R3 is a C1-C6 alkyl or a C1-C6 alkoxy group;R4 is a nitro, cyano, sulphur pentafluoride, -SO3H, -SO2NH2, an optionally substituted C1-C6 alkyl or an optionally substituted C1-C6 alkoxy group, which may be substituted with one or more fluorine, chlorine, bromine or iodine atoms or by -OH, =O, -SH, =S, NH2, =NH or -NO2 group(s); andZ1, Z2, Z3, and Z4, each and independently of each other represent a hydrogen atom, halogen atom, cyano, nitro, an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl, an aryl, a heteroaryl, an aralkyl or a heteroaralkyl group, or a compound selected from: - The compound according to any one of claims 1 or 2, wherein R4 is OMe, CF3, OCF3, fluorine, chlorine, bromine, or -SO3H, or a pharmacologically acceptable salt, solvate, or hydrate thereof.
- The compound according to any one of claims 1 to 4, wherein R3 is methyl or OMe, or a pharmacologically acceptable salt, solvate, or hydrate thereof.
- The compound according to any one of claims 1 to 5, wherein Z1 to Z4 are each and independently selected from hydrogen atom, fluorine, chlorine, bromine, and C3-C6 alkyl, or a pharmacologically acceptable salt, solvate, or hydrate thereof.
- Compound according to any one of claims 1 to 6, selected from:
- Pharmaceutical composition comprising at least one compound according to any one of claims 1 to 7, and, optionally, at least one pharmaceutically acceptable carrier(s) and/or at least one customary excipient.
- Pharmaceutical composition according to claim 8, comprising at least one compound selected from:
or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. - Compound for use in the prevention and/or treatment of a viral infection according to claim 10, wherein the compound is selected from:
or is selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. - The compound for use in the prevention and/or treatment of a viral infection according to any of claims 10 to 12, wherein the infection is an infection by an enveloped virus.
- A combination preparation for use in the treatment or prophylaxis of a viral infection according to claim 14 containing at least one compound selected from:
or one compound selected from the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyl)-chromen-4-one:Fe(III) complex and the 5,6-Dihydroxy-7-methoxy-2-(4-methoxy-phenyI)-chromen-4-one:Fe(III):NTA complex. - The combination preparation of Claim 14 or 15, wherein the further active pharmaceutical ingredient is selected from cyclosporine A, pegylated interferon-alpha-2a, pegylated interferon-alpha-2b, ribavirin, viramidine, boceprevir (victrelis), telaprevir (Incivo), SP 30, ITX 5061, RG7128, PSI-7977, NM 283, Albuferon and/or Zadaxin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13713752.7A EP2828248B1 (en) | 2012-03-23 | 2013-03-22 | Flavone derivatives and their use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12002056.5A EP2641904A1 (en) | 2012-03-23 | 2012-03-23 | Flavone derivatives and their use |
EP13713752.7A EP2828248B1 (en) | 2012-03-23 | 2013-03-22 | Flavone derivatives and their use |
PCT/EP2013/000890 WO2013139487A1 (en) | 2012-03-23 | 2013-03-22 | Flavone derivatives and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2828248A1 EP2828248A1 (en) | 2015-01-28 |
EP2828248B1 true EP2828248B1 (en) | 2019-01-23 |
Family
ID=48045409
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12002056.5A Withdrawn EP2641904A1 (en) | 2012-03-23 | 2012-03-23 | Flavone derivatives and their use |
EP13713752.7A Active EP2828248B1 (en) | 2012-03-23 | 2013-03-22 | Flavone derivatives and their use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12002056.5A Withdrawn EP2641904A1 (en) | 2012-03-23 | 2012-03-23 | Flavone derivatives and their use |
Country Status (3)
Country | Link |
---|---|
US (1) | US20150056166A1 (en) |
EP (2) | EP2641904A1 (en) |
WO (1) | WO2013139487A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104292202B (en) * | 2014-09-15 | 2015-12-09 | 云南民族大学 | A kind of flavonoid compound and its preparation method and application |
CN106117173B (en) * | 2016-06-18 | 2017-12-29 | 昆药集团股份有限公司 | A kind of breviscapine B aglycone derivative and preparation method thereof, preparation and application |
CN112121168B (en) * | 2020-04-09 | 2022-03-04 | 中国人民解放军军事科学院军事医学研究院 | Application of inhibitor in preparing medicine for treating SARS-CoV-2 pneumonia and its complication |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2375647A1 (en) | 1999-07-08 | 2001-01-18 | Patrick T. Prendergast | Use of flavones, coumarins and related compounds to treat infections |
DK1556021T3 (en) * | 2002-10-24 | 2008-04-28 | Immupharm As | Pharmaceutical compositions comprising flavonoids and menthol as well as methods of treatment using said compositions |
KR100720151B1 (en) * | 2005-12-13 | 2007-05-18 | 한국생명공학연구원 | Flavonoid comprising antiviral activity |
US20090130128A1 (en) * | 2007-08-17 | 2009-05-21 | Alberte Randall S | Antiinfective Proanthocyanidin Compounds and Methods of Use Thereof |
-
2012
- 2012-03-23 EP EP12002056.5A patent/EP2641904A1/en not_active Withdrawn
-
2013
- 2013-03-22 EP EP13713752.7A patent/EP2828248B1/en active Active
- 2013-03-22 WO PCT/EP2013/000890 patent/WO2013139487A1/en active Application Filing
- 2013-03-22 US US14/386,924 patent/US20150056166A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US20150056166A1 (en) | 2015-02-26 |
EP2641904A1 (en) | 2013-09-25 |
WO2013139487A1 (en) | 2013-09-26 |
EP2828248A1 (en) | 2015-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sui et al. | Recent advances on synthesis and biological activities of aurones | |
Yao et al. | Tatanan A from the Acorus calamus L. root inhibited dengue virus proliferation and infections | |
Lin et al. | 6-Acyl-4-aryl/alkyl-5, 7-dihydroxycoumarins as anti-inflammatory agents | |
Kwon et al. | In vitro anti-rotavirus activity of polyphenol compounds isolated from the roots of Glycyrrhiza uralensis | |
Zhao et al. | Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPS-stimulated RAW 264.7 macrophages | |
Conti et al. | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders | |
CN113015726A (en) | Ketoamide compound and preparation method, pharmaceutical composition and application thereof | |
Zhu et al. | Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats | |
CN105153142B (en) | The Furazan Derivatives and antitumor activity of cumarin parent nucleus | |
Ching et al. | Trisubstituted thieno [3, 2-b] pyrrole 5-carboxamides as potent inhibitors of alphaviruses | |
Reddy et al. | A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage | |
Iqbal et al. | Antiamoebic coumarins from the root bark of Adina cordifolia and their new thiosemicarbazone derivatives | |
Chauthe et al. | Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols | |
Spoerlein-Guettler et al. | Ferrocene and (arene) ruthenium (II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action | |
Formagio et al. | Synthesis and antiviral activity of β-carboline derivatives bearing a substituted carbohydrazide at C-3 against poliovirus and herpes simplex virus (HSV-1) | |
de Oliveira Mendes et al. | The anti-Zika virus and anti-tumoral activity of the citrus flavanone lipophilic naringenin-based compounds | |
Zhang et al. | Discovery of 9, 10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19 | |
WO2007038425A2 (en) | Anti-viral compouinds | |
EP2828248B1 (en) | Flavone derivatives and their use | |
Lee et al. | Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives | |
Liu et al. | Discovery of Camellia sinensis catechins as SARS-CoV-2 3CL protease inhibitors through molecular docking, intra and extra cellular assays | |
Liu et al. | Development of small molecule inhibitors/agonists targeting STING for disease | |
Hua et al. | Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis | |
Hu et al. | Development of novel N-hydroxypyridone derivatives as potential anti-ischemic stroke agents | |
Li et al. | In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20141008 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Owner name: TWINCORE GMBH Owner name: UNIVERSITE DE STRASBOURG |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ELHABIRI, MOURAD Inventor name: GENTZSCH, JULIANE Inventor name: HAID, SIBYLLE Inventor name: BENLLOCH-MARTIN, XAVIER Inventor name: DAVIOUD-CHARVET, ELISABETH Inventor name: GRETHE, CHRISTINA Inventor name: LANFRANCHI, DON ANTOINE Inventor name: PIETSCHMANN, THOMAS |
|
17Q | First examination report despatched |
Effective date: 20151104 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180814 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013050182 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1091345 Country of ref document: AT Kind code of ref document: T Effective date: 20190215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190423 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190523 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1091345 Country of ref document: AT Kind code of ref document: T Effective date: 20190123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190423 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190523 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013050182 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190322 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190331 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
26N | No opposition filed |
Effective date: 20191024 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190322 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190322 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130322 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190123 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240328 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240328 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240426 Year of fee payment: 12 |